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ABSTRACT
Host response to implanted biomaterials and medical devices poses tremendous challenges to their clinical
applications. Today, the quest to mitigate this immunological attack for improved longevity of these devices
remains daunting. This thesis aims to explore the use of anti-inflammatory drugs in minimizing the host response
and improve the efficacy of implantable and transplantable therapeutics.
Firstly, we developed a new non-invasive in vivo imaging technique to study the activity of early immune cells
in the host response to implanted biomaterials. A fluorescent imaging probe (Prosense680*, Perkin Elmer)
activatable by cathepsins, a class of inflammatory proteases secreted from immune cells, was used for
simultaneous biocompatibility screening of up to 8 different materials per animal in immunocompetent hairless
SKH1E mice. In this assay, the different biocompatibility properties of polystyrene beads, alginate and saline were
correlated with varying levels of cathepsin activities as acquired by imaging. Comparison of the imaging results
with traditional histological analysis validated that this new fluorescent imaging technique can be used to assess
material biocompatibility efficiently and rapidly.
We applied this new fluorescent imaging technique to investigate the in vivo spatial and temporal host
response to a subcutaneously-injected, controlled-release anti-inflammatory drug formulation. Poly-lactic-co-
glycolic (PLGA) microparticles with low loading (1.3wt%) of dexamethasone locally inhibited the activity of
cathepsin enzymes from immune cells, while high drug loading formulation (26wt%) resulted in systemic
immunosuppression. We also showed that incorporation of dexamethasone at a low loading (1.3wt%) attenuated
the coverage of polymeric microparticles by immune cell layers. Temporal monitoring of the drug effect confirmed
that incorporation of dexamethasone decreased early enzymatic activity and long-term cellular infiltration to
implanted materials.
Next, we performed in vivo subcutaneous screening of 16 small molecule anti-inflammatory drugs (NSAIDs,
polyphenols, glucocorticoids and other non-steroidal immunosuppressants) encapsulated in PLGA microparticles in
immunocompetent hairless SKH-1E mice. Using non-invasive fluorescent imaging coupled with parallel
bioluminescent imaging, we identified dexamethasone and curcumin as the most effective drugs in inhibiting the
activities of inflammatory proteases and reactive oxygen species respectively. Histological analysis also showed
that dexamethasone and curcumin encapsulated in PLGA microparticles decreased subsequent cellular infiltration
and fibrosis formation surrounding the subcutaneously injected PLGA microparticles for up to 4 weeks and 2 weeks
respectively.
Lastly, we designed hybrid alginate hydrogel microcapsules co-encapsulating pancreatic rat islets and
dexamethasone or curcumin. Uniform spherical microcapsules containing homogeneously distributed
dexamethasone (2mg/ml) or curcumin (1mg/ml) were transplanted into streptozotocin-induced C57B6/J diabetic
mice. Using a marginal islet mass of 250 islet equivalents, curcumin-loaded capsules effectively improved glycemic
control by increasing the graft survival time to 30 days compared to 15 and 21 days by control and
dexamethasone-containing capsules respectively. Curcumin also significantly reduced fibrotic overgrowth on the
encapsulated islets explanted on day 60 as evidenced by DNA fluorescent staining of the fibrotic cell layers on the
surface of the retrieved capsules.
Taken together, the results of this thesis demonstrate that anti-inflammatory drugs have the potential to
minimize the attack by host immune system and improve the efficacy or functional longevity of cell-based
therapeutics and possibly other implantable medical devices.
Thesis Advisor : Robert S. Langer, Sc.D
Title : Institute Professor
Thesis Advisor: Daniel G. Anderson, Ph.D
Title: Associate Professor of Chemical Engineering
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INTRODUCTION
The fields of material biocompatibility and drug-device combination have progressed rapidly in
the past decades. However, with the exception of the steroid-eluting pacemaker leads and the drug-
eluting stents, no other clinical success has been achieved for medical devices utilizing controlled drug
release technology to improve device biocompatibility. This thesis research aims to address several
challenges that remain the bottlenecks for achieving further understanding and improved performance
of medical devices.
The commentary in Chapter 1 discusses the background on the host response to implanted
biomaterials and medical devices. This chapter outlines the biological mechanisms underlying the host
response to implanted foreign objects, existing techniques to characterize this phenomenon and
examples of medical device failures due to this host reaction. Existing studies on the incorporation of
controlled-release anti-inflammatory drugs as a strategy to improve device performance and durability
were also reviewed.
Chapter 2 reports the development of a new non-invasive imaging technique to study the
activity of early immune cells in the early host response to implanted biomaterials. Fluorescent imaging
probes activatable by inflammatory proteases secreted from immune cells were used for simultaneous
biocompatibility screening of multiple materials in an immune-competent mouse model. Comparison of
the imaging results with traditional histological analysis validated that the new fluorescent imaging
technique can be used to assess material biocompatibility efficiently and rapidly.
The new fluorescent imaging technique in Chapter 2 was applied to study the spatio-temporal
effects of a controlled release anti-inflammatory drug as outlined in Chapter 3. Subcutaneously injected
poly (lactic-co-glycolic) (PLGA) microparticles with and without dexamethasone were investigated in
hairless immunocompetent SKH-1E mice. The influence of drug loading and release kinetics on the local
and systemic inhibition of inflammatory cellular activities was investigated by fluorescent imaging and
parallel semi-quantitative histology analysis. Temporal monitoring of host response showed that the
inhibition of inflammatory proteases in the early phase correlated with decreased cellular infiltration in
the later phase of this reaction.
Built on the understanding of drug release kinetics and the dynamics of cellular activity in the
early host response from chapter 3, in vivo subcutaneous screening of several classes of small molecule
anti-inflammatory drugs encapsulated in PLGA microparticles were performed as described in the first
part of chapter 4. Acquired by parallel non-invasive fluorescent and bioluminescent imaging during the
acute inflammation phase, the results from this chapter demonstrated that dexamethasone most
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effectively inhibited the activities of inflammatory proteases while curcumin, a polyphenol drug,
significantly decreased the presence of reactive oxygen species secreted by early immune cells. These
drugs also decreased subsequent cellular infiltration and fibrosis formation surrounding subcutaneously
injected polymeric microparticles.
The second part of chapter 4 focuses on applying the favorable finding from the subcutaneous drug
screening in a medically relevant context with a focus on improving the treatment of type I diabetes by
immuno-isolated islets. Hybrid alginate hydrogel microcapsules co-encapsulating pancreatic rat islets
and selected drugs were developed and optimized to achieve good capsule morphology and drug
loading. Curcumin effectively reduced the fibrotic response against encapsulated islets and improved
their efficacy with better glycemic control in a mouse model of chemically-induced type I diabetes.
In a different effort to improve the design and production of islet-encapsulating microcapsules,
Chapter 5 introduces a new fabrication method that allows for rapid, homogenous microencapsulation
of insulin-secreting cells with varying microscale geometries and asymmetrically modified surfaces.
Micromolding systems were developed using polypropylene mesh, and the material/surface properties
associated with efficient encapsulation were identified. Cells encapsulated using these methods
maintain desirable viability and preserve their ability to proliferate and secrete insulin in a glucose-
responsive manner. This new cell encapsulation approach enables a practical route to an inexpensive
and convenient process for the generation of cell-laden microcapsules without requiring any specialized
equipment or microfabrication process.
Lastly, the commentary in Chapter 6 summarizes the collective finding from this thesis research and
recommends directions for future research.
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CHAPTER I - BACKGROUND
1.1. HOST RESPONSE TO BIOMATERIALS AND MEDICAL DEVICES
1.1.1. Biological mechanisms underlying the host response
During the implantation of a biomaterial or biomedical device, tissue injury activates the
inflammation cascade which leads to migration of inflammatory cells to the wound site, release of
cytokines and growth factors that promote cell proliferation and protein synthesis as well was
activation of complements, blood clotting and fibrinolytic cascades [1]. Typical events following the
implantation of a material or device are depicted in Figure 1.1 below [2, 3]. The acute and chronic
inflammatory responses are of short duration occurring over the first several weeks post-
implantation[2]. Eosinophils and polymorphonuclear cells are typically present during the acute phase
while macrophages and fibroblasts are observed during the chronic phase [4]. If not controlled, this
sequence of inflammatory events can trigger the proliferation of fibroblasts which synthesize and
deposit extracellular matrix to form granulation tissues and subsequently fibrous scars surrounding the
implanted subject[5]. The duration of granulation tissue development, foreign body reaction, and
fibrosis formation varies depending upon the characteristics of the implanted materials [2]
*-ACUTE - CHRONIC- GRANULATION TISSUE -
Neutrophils 
----- 
- - - - - - ---- Macrophages
Neovascularization
-- -- - - - - - - -- Foreign Body Giant Cells
Fibroblasts
- d- Fibrosis
...... ..... Mononuclear
Leucocytes
Time
(Minutes, Hours, Days, Weeks)
Figure 1.1: Temporal variation of tissue response to implanted biodegradable microspheres [2].
Patterns of cellular recruitment change dynamically during the acute inflammatory response, chronic
inflammatory response, granulation tissue development, and foreign body reaction [2].
1.1.2. Existing techniques to characterize host response
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Traditionally, host response to biomaterial is characterized via histology analysis of excised samples
ex vivo. This approach has primarily relied on visual evaluation by trained pathologists[6]. Computer-
aided image analysis systems and immunohistochemical staining techniques have also been introduced
to gain semi-quantitative information and improve data consistency and accuracy [7-9]. These
histological approaches provide an informative end-point assessment with useful static information on
cell types, quantity and distribution. However, the quality of data acquisition and interpretation
remained variable [10].
Host response is a dynamic process involving the constant migration and recruitment of different
population of immune cells whose secretion of active biomolecules such as cytokines and enzymes play
an important role in determining the immunological response to an implanted object [2, 3]. For
example, when evaluating a polymer system encapsulating a therapeutic drug, in vivo cellular secretory
products such as inflammatory enzymes or cell signaling molecules might affect the degradation rate of
the polymeric matrix [11-13] used to encapsulate drugs, and are partly responsible for the discrepancy
between in vitro and in vivo release kinetics [14].
There remains a substantial need for new methods to provide more information in the
characterization of biocompatibility phenomena, especially quantitative approaches that acquire kinetic
information on the dynamic activities of the immune cell populations participating in the host response.
1.2. FAILURE OF IMPLANTABLE MEDICAL DEVICES DUE TO HOST
RESPONSE
1.2.1. Encapsulated islets in diabetes therapy
Implantable biomedical devices often suffer from loss of function in vivo due to changes caused in
the tissue surrounding the devices caused by surgical injuries during implantation [15]. For example,
immuno-isolated islets suffer transplanted capsules. Encapsulated islets as shown schematically in
Figure 1.2A have been investigated as a technology which allows transplantation of non-autologous
insulin-secreting cells into diabetic patients in the absence of long-term systemic administration of
immunosuppressants [16-19]. The semi-permeable alginate hydrogel membrane surrounding the islets
allows the diffusion of nutrients, oxygen and glucose while excluding antibodies and immune cells[20].
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A Glucose, 02 Insulin
Antibodies and
immune cells
Figure 1.2: Immuno-isolation of islets and fibrosis response after transplantation.
(A) Schematic illustration of microencapsulated islets in alginate hydrogel membrane[20]. (B) Deposition
of fibroblastic overgrowth on an alginate microcapsules retrieved from rat[21].
However, current development of islet encapsulation is still facing the problem of graft rejection
and the lack of long-term survival of the islet grafts[22]. The capsules suffer from attachment by the
components of the immune system such as antibodies and inflammatory cells which may induce
capsular overgrowth as shown in Figure 1.2B , especially in the case of xenografts [23, 24]. This cellular
layer can block the transport of nutrients and oxygen resulting in islet starvation. In addition, it was also
suggested that non-specific inflammation caused by surgical trauma can lead to further recruitment of
immune cells which secrete soluble cytokines[25]. These cytokines might be able to penetrate the
alginate layers causing early mass loss and impaired function of the transplanted beta cells[26].
1.2.3. Other implantable biomedical devices
Glucose biosensors are also typical examples of biomedical devices whose functions are adversely
affected by such tissue responses. Figure 1.3 illustrates a subcutaneously implanted amperometric
glucose sensor with several potential sources of declining sensor signals [15]. Glucose diffuses through
the sensor's outer membrane and is enzymatically converted to species that are detected by the
electrode. Sensors fail due to host tissue response includes membrane biofouling, fibrous encapsulation
and membrane biodegradation as well as electrode passivation due to protein adsorption and cell
attachment [15].
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fibrous encapsulation
membrane
electrical biodegradaon
failure
delamination enzyme
of membranes degradation
Figure 1.3: Schematic illustration of an amperometric glucose sensor and potential sources of
declining sensor signals [15].
Causes of device failure includes membrane biofouling, fibrous encapsulation and membrane
biodegradation as well as electrode passivation due to protein adsorption and cell attachment [15].
1.3. ANTI-INFLAMMATORY DRUGS TO IMPROVE DURABILITY OF
IMPLANTABLE DEVICES
Administration of inhibitory therapeutics such as anti-inflammatory drugs can help to improve
device performance by mitigating early tissue response and subsequent fibrosis [27]. Drug-incorporated
medical devices represent an emerging trend to localized delivery of therapeutics specifically to the site
of implantation [27]. This strategy promises to avoid the side effects of systemic administration,
minimize the effective dosage and ensure continuous drug release over a prolonged period of time [27].
However, development of devices incorporating anti-inflammatory therapeutics has mostly focused on
one or two model drugs with success in some devices but failure in others [28, 29]. The lack of an
efficient and systematic approach to characterize and compare drug efficacy in vivo hinders progress in
selecting optimal drug dosages and formulations for applications to specific devices.
Host response as discussed above significantly impairs the functions of devices that require specific
electrochemical or biochemical communication with the host microenvironment. Potent steroidal anti-
inflammatory drugs have been incorporated in medical devices to inhibit acute inflammation and
attenuate recruitment of fibroblasts and collagen production [28, 30, 31]. The success of this strategy
has been reported for cardiac pacing electrode tips in pacemakers by Medtronics in the late 1980s. The
implantation of a pacemaker lead on to the surface of the heart produces a local inflammatory response
17
membrane biofouling
at the electrode-tissue interface[28]. This response can be attenuated by local delivery of
glucocorticosteroids from the steroid-eluting tip of the electrode. Clinical studies comparing identical
electrode configurations with and without local release of dexamethasone showed the superior
performance of steroid-eluting pacemaker leads [32]. These steroid-eluting pacemaker leads are now
widely used for patients with slow heart rates, abnormal rhythms or heart failure.
Recently, several groups have attempted to adapt this approach to improve the performance of
glucose sensors. A composite of dexamethasone-loaded PLGA microparticles with poly-vinyl alcohol
hydrogel has been reported to demonstrate some ability to modulate acute and chronic inflammation in
vivo and was proposed to be used as a coating for implantable biosensors[33]. However, most of the
recent research on combining anti-inflammatory drugs and medical devices has focused on a limited
number of model drugs. Dexamethasone has been most widely used in attempts to improve biosensor
performance, possibly due to its high potency and historical success with pacemaker leads. However, no
significant improvement in sensor performance has been demonstrated. Ward et al reported that the
lifetime of amperometric glucose sensor subcutaneously implanted in dogs for several weeks was not
improved by localized delivery of dexamethasone[29]. Given the difference in the modes of
communication (electric vs electrochemical) and the sites of implantation (heart muscle vs
subcutaneous or intradermal) of the pacemaker lead and the glucose sensor, it is possible that an even
stronger inhibitory agent or a combination of several drugs is needed to minimize tissue response and
ensure acceptable communication between the sensor and the host environment. On the other hand,
dexamethasone and other potent synthetic steroids are known to have diabetogenic effect and inhibit
insulin secretion in islets[34] .Even though these potent glucocorticoids might be effective in mitigating
the host response, they might not be the most efficacious for incorporation into cell-based therapeutics
as they might adversely affects cell viability and function [35, 36]. Other classes of anti-inflammatory
drugs such as Non-steroidal Anti-inflammatory Drugs (NSAIDs), polyphenols or non-steroidal
immunosuppressants might be useful in inhibiting fibrosis while supporting cellular functionality and
survival.
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CHAPTER 2 - NON-INVASIVE IMAGING OF EARLY HOST RESPONSE
The work reported in this chapter was conducted in collaboration primarily with Dr Kaitlin M.
Bratlie. The content of this chapter has been published in whole or in part in the following peer-
reviewed journal article:
Bratlie KM, Dang TT Lyle S, Nahrendorf M, Weissleder R, Langer R, Anderson DG. "Rapid
biocompatibility analysis of materials by in vivo fluorescent imaging of inflammatory response". PLoS
ONE 2010; 5(4): e10032. doi:10.1371/ journal.pone.0010032
2.1. ABSTRACT
Many materials are unsuitable for medical use because of poor biocompatibility. Recently, advances in
the high throughput synthesis of biomaterials has significantly increased the number of potential
biomaterials, however current biocompatibility analysis methods are slow and require histological
analysis. Here we develop rapid, non-invasive methods for in vivo quantification of the inflammatory
response to implanted biomaterials. Materials were placed subcutaneously in an array format and
monitored for host responses. Host cell activity in response to these materials was imaged kinetically, in
vivo using fluorescent whole animal imaging. Data captured using whole animal imaging displayed
similar temporal trends in cellular recruitment of phagocytes to the biomaterials compared to
histological analysis. Histological analysis similarity validates this technique as a novel, rapid approach
for screening biocompatibility of implanted materials. Through this technique there exists the possibility
to rapidly screen large libraries of polymers in vivo.
2.2. INTRODUCTION
To our knowledge, there are no methods for in vivo visualization of biocompatibility or
inflammatory responses to implanted biomaterials. Traditionally, biocompatibility is determined via
histology. Histology allows for the determination of cell type and number near the implant, including
those belonging to the immune system. However, histology is an endpoint measurement, allowing
examination of only one time point per animal. Fluorescence imaging represents a set of powerful
techniques that have traditionally been employed as a method for examining tumor models[37-42],
along with inflammation resulting from arthritis[43, 44], pulmonary inflammation[45, 46], and
transplant rejection models[47].
When a biomaterial is implanted, the healing response is initiated by monocytes and neutrophils,
followed by propagation of fibroblasts and vascular endothelial cells[48]. Infiltration of inflammatory
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cells can lead to such complications as: bio-instability of glucose sensors[49]; overgrowth of
encapsulated pancreatic islets for diabetes therapy causing ischemia and, eventually, necrosis of the
islets[50]; and constrictive fibrosis following silicone implants in mammary augmentation[51].
Granulation tissue will then be formed and may appear as early as 3 to 5 days following
implantation[48]. In general, granulation tissue will ultimately form a fibrous capsule surrounding the
implant[48].
Immunological responses are dynamic processes and, as such, cell type and population at the
implant site change during the healing process[2]. The sequence of local events following implantation
is generally regarded as the tissue response continuum in which each individual event leads to the
subsequent: injury progresses to acute inflammation, which proceeds to chronic inflammation, followed
by granulation tissue formation, foreign body reaction and fibrous encapsulation[2, 52]. The presence
of eosinophils and polymorphonuclear (PMN) cells typify acute inflammatory responses while
macrophages and fibroblasts signify the chronic form[531. Neutrophils, together with monocytes and
macrophages, release cathepsins during the process of degranulation [54, 55]. Cathepsins are
proteolytic enzymes responsible for digesting foreign material [48].
Here, we describe the first methods for examining biomaterial biocompatibility in vivo, using
fluorescence reflectance screening. The novelty of this technique lies in its ability to repeatedly analyze
foreign body responses in the same animal. The macrophage recruitment and protease enzyme activity,
both of which serve as markers of biocompatibility, were monitored in vivo, in real-time. We believe the
methods developed here provide the first rapid techniques for parallel determination of biomaterial
biocompatibility in vivo in a non-invasive manner.
2.3. MATERIALS AND METHODS
2.3.1. Molar Absorptivity.
The absorbance of the two fluorophores, ProSense-680 and F4/80 pan macrophage monoclonal
antibody conjugated to Fluorescein isothiocyanate (FITC), were monitored using UV/Vis absorbance
spectroscopy over the 200 to 800 nm range. Solutions were diluted in 0.9% w/v NaCl and housed in 1
cm path-length quartz cuvettes. Absorbances were measured on a Cary 100 Bio UV/Vis
Spectrophotometer.
2.3.2. Ethics Statement.
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The research protocol was approved by the local animal ethics committees at Massachusetts
Institute of Technology (Committee on Animal Care) and Children's Hospital Boston (Institutional Animal
Care and Use Committee) prior to initiation of the study.
2.3.3. Animals.
8-12 week old male SKH1 mice were obtained from Charles River Laboratories (Wilmington, MA).
The mice were maintained at the animal facilities of Massachusetts Institute of Technology, accredited
by the American Association of Laboratory Animal care, and were housed under standard conditions
with a 12-hour light/dark cycle. Both water and food were provided ad libitum.
2.3.4. Injections.
Injections were performed in accordance with ISO 10993-6: 2001. Prior to injection all materials
were sterilized. Saline was sterilized via 0.22 pm filtration; alginate was autoclaved for 20 min. at 121*C;
and polystyrene particles were washed in 70% ethanol and re-suspended in sterile saline. The mice
were anesthetized via isoflurane inhalation at a concentration of 1-4% isoflurane/balance 02 to
minimize movement. Their backs were scrubbed with 70% isopropyl alcohol and the animals were
injected with saline, a solution of 2%-w/v alginate (Protanal LF 10/60, FMC BioPolymer, Newark, DE,
having high guluronic acid composition (65-75%), mean molecular weight of 180kDa), or 10%-w/v
polystyrene beads (3.0 pm, Sigma Aldrich, St. Louis, MO) in an array format on the mouse's back. Eight
injections were made in each mouse in a random fashion to establish position-dependent inflammatory
responses. Injection volumes ranged from 30 - 100 p. All experiments were conducted in
quadruplicate for each imaging time-point. In addition, a set four mice were imaged at every time-point
and sacrificed at the 28 day time-point.
2.3.5. Imaging.
The following two imaging agents were co-injected into the tail vein 24 hours before in vivo
fluorescence imaging: ProSense-680 (VisEn Medical, Woburn, MA, excitation wavelength 680 ± 10 nm,
emission 700 ± 10 nm)[40] for imaging cathepsin activity, 2 nmol in 150 pl sterile Phosphate Buffered
Saline (PBS), and FITC-mAb F4/80 (Abcam, Cambridge, MA, excitation wavelength 495 nm, emission 521
nm) for imaging macrophage recruitment, 5 Ig in 100 pl sterile PBS.
In vivo fluorescence imaging was performed with an IVIS-Spectrum measurement system (Xenogen,
Hopkinton, MA). The animals were maintained under inhaled anesthesia using 1-4% isoflurane in 100%
oxygen at a flow rate of 2.5 L/min. A binning of 8 x 8 and a field of view of 13.1 cm were used for
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imaging. Exposure time and f/stop - the relative size of the opening of the aperture - were optimized for
each acquired image. Data were acquired and analyzed using the manufacturer's proprietary Living
Image 3.1 software. All images are presented in fluorescence efficiency which is defined as the ratio of
the collected fluorescent intensity to an internal standard of incident intensity at the selected imaging
configuration. Regions of interest (ROls) were determined around the site of injection. ROI signal
intensities were calculated in fluorescent efficiency. Images were obtained 1, 3, 7, 14, 21, and 28 days
post-injection with four replicates imaged at each time point. A separate set of four replicates were
imaged at all six time points.
2.3.6. Histology.
Histology evaluated the severity of inflammation resulting from the injected biomaterials. Mice
were euthanized via CO2 asphyxiation and the injected biomaterial and surrounding tissue were excised.
The tissues were then fixed in 10% formalin, embedded in paraffin, cut into 5 pm sections, and stained
using hematoxylin and eosin (H&E) for histological analysis by a board certified pathologist. Fibrosis was
rated on a scale where a zero involved no fibrosis, a one indicated partial coverage with one to two
layers of fibrosis, a two is designated a thicker fibrotic layer that nearly covered the implant, and a three
denoted concentric fibrotic coverage of the polymer. Both polymorphonuclear (PMN) cells and
macrophages were rated on a scale where no observed cells were indicated with a zero, scattered cells
scored a one, numerous cells clustering on the sides of the polymer scored a two, and numerous cells
surrounding the material resulted in a three.
2.3.7. Statistical Analysis.
The values of the histologic scores and the ROls were averaged and expressed as the mean
standard error of the mean. Comparisons of values were performed by the Student's unpaired two-
tailed t-test. P values less than 0.05 were considered significant.
2.4. RESULTS
2.4.1. Linearity of Fluorescence Response to Dose Concentration.
Prior to quantifying responses in vivo, the linearity of the in vitro fluorescence response to
concentration of dye was assessed, facilitated by the stationary superficially implanted target
Fluorescence intensity F is proportional to the intensity of the excitation beam that is absorbed by the
system. That is,
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F =K'(O 
-I) (1)
Where I is the intensity of the incident excitation beam and I is the detected fluorescence
intensity after traversing a length b of the medium - in this case - the tissue of the animal. The constant
K' depends upon the quantum efficiency of the fluorescence process. In order to relate F to the
concentration c of the fluorescing species, Beer's law can be written in the form:
I =10~*b
10 (2)
Where e is the molar absorptivity of the fluorescing molecules and ebc is the absorbance.
Inserting Beer's law into equation 1, we obtain:
F = K'I 0 (1-_10-e*c). 3
Which can be approximated for absorbances less than 0.05 to:
F = 2.3K'EscI0 (4)
Assuming that I is constant, the fluorescence intensity is linearly proportional to concentration at
low absorbances. The molar absorptivities were determined by UV-visible absorbance to be 2.90 ± 0.04
x 106 M 1 cm' and 2.30 ± 0.06 x 10' M 1 cm 1 for ProSense-680 and FITC mAb-F4/80, respectively. With
an in vivo penetration depth for visible light of ~5 mm in reflectance mode,[37] the onset of nonlinear
relations between fluorescence and concentration would present at doses 5 and 2.5 times larger than
those injected for FITC mAb-F4/80 and ProSense-680, respectively, indicating the ability for relative
quantitative analysis.
2.4.2. In Vivo Imaging of Cathepsin Activity and Macrophages.
Mice were injected with alginate, polystyrene, or saline in an array format (Figure 2.1) in volumes
of 30, 50, 70, and 100 ptl. Alginate is a bio-inert material used in a variety of biomedical applications
including encapsulation of insulin producing islets for diabetes therapy [56-59], wound healing[60, 61],
implants for cardiac remodeling following infarction[62, 63]. In contrast, Polystyrene exhibits high
cellular adhesive properties, induces a strong inflammatory response and was chosen as a positive
control. Polystyrene particles below 10 ptm activate macrophages and are easily phagocytosed[64],
allowing them to serve as positive controls. Saline serves as a negative control to assess the background
fluorescence level and aid in determination of the detection limit. After injection, the mice were imaged
at prescribed time points for cathepsin activity and macrophages as shown in Figures 2.2A-C and 2.3A-C.
23
Fluorescent regions of interest (ROls) were quantified for each image and are presented in Figures
2.2D,E and 2.3D,E for cathepsin activity and macrophages recruitment.
Qualitatively, for saline, the cathepsin activity and macrophage fluorescent signal appear to be very
low with the exception of cathepsin activity on day 7. For polystyrene, cathepsin activity follows very
similar trends wherein protease activity is detected on day one, peaks at three weeks, and begins to
decline at four weeks. Recruitment of immune cells to alginate displays a different trend than
polystyrene in which cathepsin activity remains constant from the first day to the fourth week.
Macrophage recruitment for polystyrene reached a plateau at day seven. Alginate arrived at this
plateau earlier, at the third day.
Quantitative performance criteria of methods are necessary in determining whether this technique
is suitable in analyzing inflammatory responses. Detection limits are defined as the blank plus three
times the standard deviation of the blank and limit of quantification (LOQ) is ten times the standard
deviation of the blank. For macrophage detection, the detection limit is a fluorescence efficiency of 9.4
x 10-7 and the LOQ is a fluorescence efficiency of 2.3 x 10-6. ProSense-680 has a fluorescence efficiency
detection limit of 1.1x 10-5 and the fluorescence efficiency LOQ is 1.8 x 10-5. Quantification of
fluorescence efficiency of both cathepsin activity and macrophage recruitment is above the LOQ as
shown in Figures 2.2 and 2.3. Cathepsin activity on the first day after injection of polystyrene was not
above the LOQ and therefore not included in Figure 2.2D. Macrophage recruitment on day one for
alginate and polystyrene were also below the LOQ and not included in Figure 2.3D and E.
2.4.3. Histology
Validation of the in vivo imaging technique for biocompatibility described required histologic
analysis subsequent to each imaging time point. Several inflammation markers were quantified: PMNs,
macrophages, and fibrosis. PMNs and macrophages were scored on the basis of zero being normal cell
populations, one being scattered cells, two being numerous cells mostly populating the sides of the
polymer, and three being the most severe where numerous cells surrounded the material. Quantified
scores and representative images are shown in Figures 2.4 and 2.5, respectively. Minimal PMNs are
seen infiltrating the injection site for saline whereas for alginate neutrophils completely surround the
injection site from day one to day 28. For polystyrene, neutrophils are present the first day following
injection, reaching a maximum population at day 21 and subsequently decreasing.
Macrophage recruitment for the saline injections is very low (Fig. 2.4B). Slightly elevated levels of
macrophages on days three and seven likely result from trauma of the injury, not the biocompatibility of
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saline, and agrees with previous results[65]. A more pronounced reaction occurs in response to
polystyrene and alginate. The macrophage signal for polystyrene reaches a plateau seven days post-
injection, while that for alginate levels out at day three. The size of the polystyrene particles (3.0 pm)
lends to being easily phagocytosed, which can be seen in Figure 2.5.
Fibrosis of the implants was also analyzed histologically in which a score of zero denotes no fibrosis,
one signifies partial coverage with one to two layers of fibroblasts, two indicates a thicker layer nearly
covering the implant, and three represents concentric fibrotic coverage of the polymer. As seen in
Figure 2.4C, fibrosis for alginate and polystyrene gradually increases reaching a maximum at fourteen
days. This observation is in line with previous findings[66] in which wound dressings of calcium alginate
were grafted in porcine models and found fibrosis to reach a maximum at 14 days. The slight decrease
in fibrosis scoring at day 28 might result from myofibroblasts contracting the wound as part of the
healing process[67].
2.5. DISCUSSION
Chemical signals responsible for invoking a response toward implanted biomaterials may include
proteins from invading bacteria, clotting system peptides, complement products, and cytokines that
have been released by macrophages located in the tissue near the implantation site[68]. Another group
of chemical attractants are chemokines which recruit neutrophils and monocytes from the blood[69].
Macrophages derive from monocytes[70]. Macrophages and monocytes can phagocytose cellular debris
and pathogens, and stimulate lymphocytes and other immune cells to respond to the pathogen.
Typically for acute inflammation, neutrophil recruitment peaks 1 - 2 days after implantation and
gradually resolves after 7 - 10 days followed by macrophage migration at 1 - 2 days after injury[71].
Fibroblasts typically infiltrate at 2 - 3 days reaching a maximum population at 3 - 4 days[71]. Both
macrophages and fibroblasts disperse after 5 - 9 days[71]. Chronic inflammation also begins with
recruitment of neutrophils[72]. Additionally, protease levels are reported to be higher in chronic
wounds[73]. Fibroblasts and macrophages become numerous one to two weeks after injury and
diminish at six weeks[71, 74]. Histologic analysis and in vivo fluorescence imaging showed very similar
trends in macrophage recruitment and also in comparing cathepsin activity derived from in vivo imaging
to neutrophils evaluated via histology, suggesting that a significant portion of the protease secreted
derives from neutrophils. Cathepsin may also derive from macrophages[75]. Christen et a/[47] have
shown that ~75% of the prosense signal is macrophage derived in transplant rejection. Early markers of
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inflammation - macrophages and cathepsin activity - have been chosen to assess biocompatibility of
various polymers.
Traditionally, the local pathological effect of a material on living tissue that is placed into an implant
site is evaluated at both the gross level and the microscopic level. Various biological parameters such as
cellular responses and histopathological changes are evaluated via ex vivo histology[52]. The throughput
of histology is typically on the order of days to several weeks and involves steps such as fixation,
embedding, processing, and staining. In vivo fluorescent images can be acquired in minutes and only
require anesthetization of the subject, thus greatly reducing the time required to screen libraries of
compounds. Recently, Sabaliauskas et al[76] have made advances in improving the throughput of
histology by automating and digitizing data acquisition. Gersner et al[77] have developed laser scanning
cytometry methods to quantify histological specimens, increasing the throughput of analysis. Specimen
preparation still remains a costly, labor-intensive bottleneck in histology and, thus, in biocompatibility
screening.
Aside from quantitative detection limit and LOQ, comparison of the dynamic ranges between
histology and in vivo imaging is also necessary in determining the abilities of fluorescence imaging in
assessing immune responses. In comparing histologic scores of polystyrene with fluorescence imaging
for cathepsin activity (neutrophils), scores greater than 0.5 are above the detection limit, meaning that
the injection sites are distinguishable from the background autofluorescence of the mouse. Histologic
scores above 1 appear to correlate to fluorescence efficiencies above the LOQ for cathepsin activity
(neutrophils). Comparing fluorescence imaging to histologic scores for macrophages leads to the
conclusion that the detection limit and LOQ obtained for in vivo imaging corresponds to a histologic
score of 1.5, indicating the possibility for false negatives in detecting macrophage infiltration and the
necessity for histologic analysis. However, the use of amplification mechanisms such as use of
fluorescent nanoparticles avidly taken up by macrophages[40] will likely enhance sensitivity. Although
this technique is semi-quantitative owing to the poor depth penetration of visible light[37], in
conjunction with histology it possesses the ability to transform the rapidity with which libraries of novel
materials are assessed for biocompatibility.
2.6. CONCLUSION
The methods developed here provide for rapid, in vivo analysis of several different materials
simultaneously, thereby allowing for rapid, kinetic analysis of the foreign body response to a number of
biomaterials, as well as eliminating labor intensive tissue processing steps typically necessary for
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histology. We anticipate that in vivo fluorescence imaging may therefore help address bottlenecks in
analyzing biocompatibility of polymers and aid in understanding foreign body responses to biomaterials.
In vivo fluorescence imaging also holds the advantage of monitoring temporal immune cell changes,
thus eliminating mouse-to-mouse variations present when making a static histological assessment.
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Figure 2.1: Subcutaneous Injection arrays.
Three array formats used for injecting saline and polymers subcutaneously in mice where A is 30 pil, B is
50 i, C is 70 pl, and D is 100 il
28
2.0 d) 20 e
016 , Day 3
a Day 7 1.5
OaDay4
.A Day 14
+ Day 21
D 0. -4 Day 28.
'.0
0. * DaylI
240 30.5 * Day 7
OA A Day 14
D ay 21
LL 0. L 0 41 Day 28
20 40 60 80 100 20 40 60 80 100
Injection Volume (pl) Injection Volume (pl)
Figure 2.2: Time evolution of cathepsin activity in response to injected materials fluorescently imaged.
In vivo fluorescence imaging using ProSense 680 for cathepsin activity at various time points for A)
saline, B) polystyrene, and C) alginate. The scale bar ranges 0 - 6 x 10 ~ in fluorescence efficiency. The
quantified fluorescence efficiencies of cathepsin activities are shown for D) polystyrene and E) alginate
as the mean with standard deviation. Symbols represent data points and lines represent linear
regressions.
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Figure 2.3: Time evolution of macrophage response to injected materials fluorescently imaged.
In vivo fluorescence imaging of F4/80 pan macrophage antibody at various time points for A) saline, B)
polystyrene, and C) alginate. The scale bar ranges 0 - 1.5 x 10~4 in fluorescence efficiency. The
quantified fluorescence efficiency of F4/80 pan macrophage responses are shown for D) polystyrene and
E) alginate as the mean with standard deviation. Symbols represent data points and lines represent
linear regressions.
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Figure 2.4: Histological scores of materials subcutaneously injected.
Histological scores of A) neutrophils, B) macrophages, and C) fibrosis determined for tissue excised at
various time points with injections of saline (0) , polystyrene (A), and alginate (m). Values shown are
means with standard deviations.
31
a)3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
.2
I
25 30
c)
-
,1
~ b)
-T
Day
1 3 7 14 21 28
C
rU
C
Figure 2.5: H&E staining of representative sections subcutaneously injected materials.
Representative sections stained with H&E are shown for saline, polystyrene, and alginate at various time
points (1, 3, 7, 14, 21, and 28 days post-injection). (Magnification 20x, scale bar = 100 prm)
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CHAPTER 3 - IMAGING SPATIHYTEMPORAL EFFECTS OF A CONTROLJED-
RELEASE ANTI-INFIAMMATORY DRUG
The content of this chapter has been published in whole or in part in the following peer-reviewed
journal article and incorporated into the following patent applications.
Dang TT Bratlie KM, Bogatyrev SR, Chen XY, Langer R, Anderson DG. "Spatiotemporal effects of a
controlled release anti-inflammatory drug on the cellular dynamics of host response". Biomaterials
2011;32(19):4464-70
Anderson D.G, Langer R, and Dang TT. "Hybrid Microcapsules containing islets and anti-
inflammatory drugs for diabetes therapy". U.S.S.N. 61/444206, filed on Feb. 2011.
Anderson D.G, Langer R, and Dang TT. "Hydrogel-encapsulated cells and anti-inflammatory drugs".
U.S.S.N. 13/400,382 and PCT/US2012/025806, filed on Feb 2012.
3.1. ABSTRACT
In general, biomaterials induce a non-specific host response when implanted in the body. This
reaction has the potential to interfere with the function of the implanted materials. One method for
controlling the host response is through local, controlled release of anti-inflammatory agents. Herein,
we investigate the spatial and temporal effects of an anti-inflammatory drug on the cellular dynamics of
the innate immune response to subcutaneously implanted poly(lactic-co-glycolic) (PLGA) microparticles.
Noninvasive fluorescence imaging was used to investigate the influence of dexamethasone drug loading
and release kinetics on the local and systemic inhibition of inflammatory cellular activities. Temporal
monitoring of host response showed that inhibition of inflammatory proteases in the early phase was
correlated with decreased cellular infiltration in the later phase of the foreign body response. We
believe that using controlled-release anti-inflammatory platforms to modulate early cellular dynamics
will be useful in reducing the foreign body response to implanted biomaterials and medical devices.
3.2. INTRODUCTION
One major challenge to clinical application of biomaterials and medical devices is their potential to
induce a non-specific host response[10, 15, 49, 78-82]. This reaction involves the recruitment of early
innate immune cells such as neutrophils and macrophages, followed by fibroblasts which deposit
collagen to form a fibrous capsule surrounding the implanted object [2, 3, 10, 82, 83]. Fibrotic cell layers
can hinder electrical[28] or chemical communications and prevent transport of analytes [84-86] and
nutrients, thus leading to the eventual failure of many implantable medical devices such as glucose
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sensors[15, 49, 87], neural probes[30], immunoisolated pancreatic islets[88-90] and biodegradable
polymeric stents[79].
The incorporation of controlled-release delivery systems of anti-inflammatory drugs into medical
devices has been proposed to mitigate host response and improve device durability [6, 27, 91-93]. This
approach has shown promise in a number of clinical applications. For example, controlled elution of
steroids from pace-maker leads has reduced fibrosis formation and enhanced long-term electrical
communication between the leads and surrounding cardiac tissue[28]. However, similar attempts to
improve the performance of other medical devices such as implanted glucose sensors [29] and
immunoisolated islets for diabetes therapy have proven challenging [10]. There remains a substantial
need to better understand the immunomodulatory effects of anti-inflammatory drugs on the host-
tissue biology at the implant site[27]. Such knowledge can lead to better design of controlled-release
drug delivery systems to improve the biocompatibility of implanted medical devices.
Researchers developing controlled-release drug formulations to mitigate host response have largely
focused on decreasing the number of inflammatory cells infiltrating the host-device interface. Hickey et
al. designed a mixed microsphere system containing dexamethasone, a steroidal anti-inflammatory
drug, to achieve zero-order in vitro release kinetics and to suppress tissue response to thread-induced
injuries in rats for up to one month[94, 95]. Recent studies on a hydrogel composite containing
dexamethasone-loaded PLGA particles also suggested that sustained release of this drug may minimize
the inflammatory reactions at the tissue-material interface [33, 96, 97]. While these studies have
provided invaluable information, they only addressed the effects of these drug delivery systems via ex
vivo analysis of the cell types, quantity and distribution in excised tissues. However, various factors in
the design of controlled -release formulations such as drug selection, drug loading, particle sizes and
corresponding release kinetics can dynamically affect a range of biological activities in the host
response. The presence of anti-inflammatory drugs may alter not only the quantity and variety of
immune cells recruited but also the kinetics of cellular activities such as the secretion of inflammatory
enzymes or cell signaling pathways[98, 99]. In vivo cellular secretory products might affect the
degradation rate of the polymeric matrix[11-13] used to encapsulate drugs, and are partly responsible
for the discrepancy between in vitro and in vivo release kinetics[14]. Therefore, we hypothesize that
monitoring the spatial and temporal dynamics of enzymatic activity in the host response will offer new
insight into the efficacy of controlled-release systems of anti-inflammatory drugs.
In this study, we examined the real-time effects of controlled-release anti-inflammatory
therapeutics on the host response to subcutaneously implanted polymeric materials. Poly(lactic-co-
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glycolic) (PLGA 50/50) microparticles with and without dexamethasone were subcutaneously injected in
a six-spot array on the dorsal side of immunocompetent mice. Monitoring the in vivo activity of
cathepsins, a class of inflammatory proteases, by noninvasive fluorescent imaging revealed that
microparticles with low drug loading (1.3wt%) locally inhibited these enzymes, while high drug loading
(26wt%) formulation resulted in systemic immunosuppression. The low dexamethasone loading
(1.3wt%) was sufficient to attenuate the coverage of the implanted polymer by fibrotic cell layers.
Temporal monitoring of the anti-inflammatory effect was carried out by in vivo imaging and ex vivo
histological analysis.
3.3. MATERIALS AND METHODS
3.3.1. Fabrication and characterization of PLGA microparticles
Microparticles with or without dexamethasone were prepared using a single-emulsion method
[100] with biodegradable PLGA 50/50 (inherent viscosity of 0.95-1.2OdL/g) from Lactel (Pelham, AL).
Typically, a 5mL solution of PLGA and dexamethasone dissolved in dichloromethane, at concentrations
of 40mg/ml and 2mg/ml respectively, was quickly added to a 25mL solution of 1% (w/v) polyvinyl
alcohol and homogenized for 60s at 5000rpm (Silverson L4R, Silverson Machines Ltd., Cheshire,
England). The resulting suspension was quickly decanted into 75mL of deionized water and stirred for
30s prior to rotary evaporation (Buchi Rotavap, Buchi, Switzerland) for 3min. The suspension was
washed five times by centrifugation at 3000rpm for 3min. The particles were collected by filtration using
0.2p.m filter, flash-frozen in liquid nitrogen, and lyophilized to dryness. Particle size distribution and
morphology were examined by Scanning Electron Microscopy (JSM-6060, Jeol Ltd., Peabody, MA, USA).
Fluorescence spectra of the PLGA polymer microparticles were collected by a Fluorolog-3
spectroflurometer (Horiba Yvon Jobin, Edison, NJ, USA). The dexamethasone loading of all microparticles
was determined by dissolving 2mg of microspheres in 1mL of acetonitrile and comparing the resulting
UV absorbance at 234 nm to a standard curve of known concentrations of dexamethasone in
acetonitrile.
3.3.2. In vitro drug release kinetics
The sample preparation and separation methods reported elsewhere were utilized to study the
release of drug from microparticles[101]. Briefly, 3.5mg of dexamethasone-loaded PLGA microparticles
were suspended in 1mL of 0.9% (w/v) NaCl solution in a 1.5mL centrifuge tube. The centrifuge tube was
incubated at 37*C on a tilt-table (Ames Aliquot Mixer, Miles). At predetermined intervals, the tube was
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centrifuged at 12krpm for 5min using an Eppendorf 5424 microcentrifuge. The supernatant was
collected and replaced with an equal volume of fresh 0.9 % (w/v) aqueous NaCl solution. After a release
period of thirty days, the suspension of remaining particles was completely dissolved in acetonitrile
overnight. The concentration of dexamethasone in all collected samples was quantified using UV
absorbance at 234nm against a standard curve of known drug concentrations. The percentage of drug
release at each time point was calculated by normalizing the cummulative amount of drug collected at
each point with the total amount of drug initially encapsulated in the particles. The release kinetics
reported for each particle formulation was obtained from the average of quadruplicate experiments.
3.3.3. Animal care
The animal protocol was approved by the local animal ethics committees at Massachusetts Institute
of Technology (Committee on Animal Care) and Children's Hospital Boston (Institutional Animal Care
and Use Committee) prior to initiation of the study. Male SKH-1E mice at the age of 8-12 weeks were
obtained from Charles River Laboratories (Wilmington, MA, USA). The mice were housed under standard
conditions with a 12-hour light/dark cycle at the animal facilities of Massachusetts Institute of
Technology, accredited by the American Association of Laboratory Animal Care. Both water and food
were provided ad libitum.
3.3.4. Subcutaneous injection of polymeric microparticles
Before subcutaneous injection of microparticles, mice were kept under inhaled anesthesia using 1-
4% isoflurane in oxygen at a flow rate of 2.5L/min. Lyophilized microparticles with or without
encapsulated drug were suspended in sterile 0.9% (w/v) phosphate buffered saline at a concentration of
50mg/mL. A volume of 100pL of this suspension was injected subcutaneously via a 23G needle at each
of the six spots on the back of the mouse.
3.3.5. In vivo fluorescent imaging of whole animals
Mice were started on a non-fluorescent alfalfa-free diet (Harlan Teklad, Madison, WI, USA) three
days prior to subcutaneous injections of microparticles and maintained on this diet till the desired
sacrifice time point for tissue harvesting. The imaging probe ProSense-680 (VisEn Medical, Woburn, MA,
USA), at a concentration of 2nmol in 15OpI of sterile phosphate buffered saline, was injected into the
mice tail vein. After 24 hours, in vivo fluorescence imaging was performed with an IVIS-Spectrum
measurement system (Xenogen, Hopkinton, MA, USA). The animals were maintained under inhaled
anesthesia using 1-4% isoflurane in oxygen at a flow rate of 2.5L/min. For monitoring cathepsin activity,
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whole-animal near-infrared fluorescent images were captured at an excitation of 605nm and emission
of 720nm and under optimized imaging configurations. A binning of 8x8 and a field of view of 13.1cm
were used for imaging. Exposure time and f/stop (the opening size of the aperture) were optimized for
each acquired image. Background autoflourescence of PLGA particles was also imaged at an excitation
of 465nm and emission of 560nm. Data were analyzed using the manufacturer's Living Image 3.1
software. All images are presented in fluorescence efficiency which is defined as the ratio of the
collected fluorescent intensity normalized against an internal reference to account for the variations in
the distribution of incident light intensity. Regions of interest (ROls) were determined around the site of
injection. ROI signal intensities were calculated in fluorescent efficiency.
3.3.6. Tissue harvest and histology processing
At the desired time points, mice were euthanized via CO2 asphyxiation. The injected microparticles
and 1cm 2 area of full thickness dermal tissue surrounding the implant were excised, placed in histology
cassettes and fixed in 10% formalin overnight. Following fixation, the tissues were dehydrated by
transferring the cassettes to 70% ethanol solutions. The polymer particles with surrounding fixed tissues
were embedded in paraffin and sectioned into samples of 5im thickness. These samples were stained
with hematoxylin and eosin (H&E) for histological analysis.
3.3.7. Histology analysis by laser scanning cytometry
The extent of cellular infiltration to injected polymer spots was determined by semi-quantitative
imaging cytometry using the iCys Research Imaging Cytometer with iNovator software (CompuCyte,
Cambridge, MA, USA). A scanning protocol for quantification was configured with excitation by blue
488nm laser and a virtual channel for hematoxylin detection. Low resolution tissue scans with the 20x
objective were performed to capture preliminary images of all tissue sections in each slide. High
resolution tissue scans were subsequently acquired using the 40x objective and step size of 0.5pm. The
threshold in the hematoxylin channel for detection of cell nuclei was optimized to selectively contour
individual nuclei. Cross-sectional areas of the polymer spots excluding the dermal and skeletal tissues
were defined. The nuclei number and nuclei area measurements were taken from within these regions.
The extent of cellular infiltration into each polymer spot was calculated as the ratio of the total nuclei
area to total polymer cross-sectional area.
3.3.8. Statistical analysis
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The values of the fluorescent signals and the extent of cellular infiltration were averaged and
expressed as the mean ± standard error of the mean. Comparisons of values were performed by the
Student's two-tailed two-sample t-test. P-values less than 0.05 were considered significant.
3.4. RESULTS AND DISCUSSION
3.4.1. Spatial effect of a controlled-release anti-inflammatory drug
3.4.1.1. Effect of drug loading on controlled-release properties
We first investigated the inhibitory effect of microparticles with different loadings of an anti-
inflammatory drug. Dexamethasone, a synthetic steroid, was selected for incorporation into PLGA
microparticles because it is the most potent long-acting glucocorticoid [102] which has been reported to
decrease cellular recruitment to implanted biomaterials[30, 31, 95, 97] and to minimize fibrotic
deposition on FDA-approved pace-maker leads[28]. PLGA particles with or without different drug
loadings were fabricated by a water-in-oil emulsion method. Each formulation of drug-loaded particles
was tested via subcutaneous injections at three alternating sites on the dorsal side of each mouse as
shown in the injection scheme (Figure 3.1A). Control particles without encapsulated drug were similarly
administered at the three remaining sites on the same mouse. Each mouse was imaged 24 hours after
intravenous administration of Prosense680, a near-infrared fluorescent probe to detect the activity of
cathepsin enzymes which are inflammatory proteases secreted by immune cells[103-105].
Figure 3.1B-C shows the imaging results at day 4 for two representative mice corresponding to two
particle formulations with low (1.3wt%) and high (26wt%) drug loadings. For the mouse with low loading
particles (Figure 3.1B), cathepsin activity of inflammatory cells was observed at three injection sites with
control particles. This near-infrared fluorescent signal was absent for the drug-loaded particles at the
remaining sites on the same mouse. The juxtaposition of cathepsin-absent sites next to cathepsin-active
sites suggested that the anti-inflammatory effect was spatially localized at the injection sites of
dexamethasone-loaded particles. Though the mechanism of action for dexamethasone is not completely
understood, it is known to act via a variety of pathways[99] resulting in the attenuation of inflammatory
cell cascades when administered systemically[106]. Ex vivo histology studies also reported that this drug
decreases fibroblastic recruitment and collagen production at implant sites[107]. Our data showed in
vivo for the first time that controlled-release formulations of dexamethasone (1.3wt% drug loading)
exhibited specific and localized inhibition of cathepsin activity in host response to subcutaneously
implanted materials.
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With the higher drug loading, there appeared to be a systemic immunosuppressant effect causing
the disappearance of cathepsin signals from all six injection sites (Figure 3.1C). This might be due to the
significant initial burst release from the particles with higher drug loading, as illustrated by the in vitro
drug release profile (Figure 3.1D). Several mice administered with particles of high drug loading died
after 7-10 days. Conversely, mice receiving particles with low drug loading maintained healthy body
conditions till sacrifice at 28 days. Understanding the effect of drug loading on the in vivo inhibitory
properties is important in selecting drug delivery formulations for incorporation into medical devices.
Choosing an appropriate anti-inflammatory drug release profile may minimize unwanted side effects of
systemic circulation, while ensuring sufficient mitigation of the host response to achieve long-term
device performance.
3.4.1.2. Anti-inflammatory drug attenuated coverage of implanted polymer by immune cell
layers
When we imaged the mice with low drug-loading particles at both near-infrared and green
wavelength conditions (Figure 3.2), we discovered an interesting phenomenon relating to the optical
properties of immune cell layers surrounding the injected polymer particles. Shown here are
representative images from one mouse, displaying near-infrared (Figure 3.2B) and green (Figure 3.2C)
fluorescent signals overlayed on a gray photograph at day 10 after subcutaneous injection of particles.
Figure 3.2D shows the multiplex image combining the two fluorescent signals. Three injection sites with
control particles showed fluorescence under near-infrared excitation, but no green signal when imaged
at visible wavelengths. Conversely, for the remaining injection sites with drug-loaded particles, green
fluorescence was detected but near-infrared signal was absent. This phenomenon was observed
consistently in other mice. In addition, the fluorescent excitation-emission spectra of solid PLGA 50/50
particles in vitro (Figure 3.2E) revealed that both control and drug-loaded microparticles gave strong
autofluorescence in the green visible wavelengths but undetectable signals in the near-infrared region.
We hypothesized that the presence or absence of immune cell layers accounted for the difference
in fluorescent signals observed in figures 3.2B and 3.2C. As illustrated in figure 3.2F, inflammatory cells
were extensively recruited to the injection sites of control particles, covering them in compact cellular
layers and reducing the green polymer auto-fluorescence by tissue scattering and absorption[108].
However, infiltration of immune cells to the drug-loaded particles was inhibited due to the anti-
inflammatory effect of dexamethasone. The absence of immune cells enabled the detection of green
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autofluorescence from the polymer. No near-infrared autofluorescent signal was detected from the
drug-loaded particles because PLGA 50/50 polymer does not autofluoresce in this region.
Our hypothesis was confirmed by ex vivo imaging of the excised polymer particles. Figures 3.2G-1
show the excised mouse skin with the dermal-subcutaneous surface facing upwards, exposing the
polymer microparticles to the imaging camera. A colored photograph of the same tissue (Figure 3.2G)
verified that the control polymer spots were compacted in extensive fibrotic tissue while the drug-
loaded microparticles remained flattened against the skin, with minimal coverage by immune cell layers.
In Figure 3.2H, the near-infrared cathepsin activity of the ex vivo tissue was consistent with the in vivo
data. At the green wavelength condition in Figure 3.21, ex vivo control particles also showed some auto-
fluorescence that was not as intense as that of the drug-loaded particles. This weak auto-fluorescence of
the control particles was not seen during in vivo imaging as the polymer spots were underneath the skin
layer. Overall, our data suggest that inhibition of cathepsin activity by a controlled-release anti-
inflammatory drug correlates with decreased coverage of the implanted particles by immune cell layers.
Our observation regarding the optical properties of immune cell layers may be used to noninvasively
monitor long term fibrosis in response to subcutaneously implanted materials.
3.4.2 Temporal effect of a controlled-release anti-inflammatory drug
3.4.2.1. Time-evolution of cathepsin activity
The in vivo host response to implanted materials is a dynamic process that involves many different
cell types and biological pathways. Neutrophils, monocytes and macrophages release cathepsins during
the process of degranulation[54, 109].To kinetically monitor the effect of controlled-release
dexamethasone on the activity of these immune cells, cathepsin activity was imaged in mice
administered with dexamethasone-loaded particles (1.3wt% drug loading) following the timeline in
Figure 3.3A. The results for one representative animal at four different time points are shown in Figure
3.3B. Cathepsin activity in response to control PLGA 50/50 particles was highest at days 3 and 10, and
decreased significantly at later time points. However, for the microparticles containing dexamethasone,
such cellular activity was suppressed at earlier time points and remained absent over the entire period
of 28 days. Quantification of the time-evolution of this cathepsin activity is presented in Figure 3.3C
showing statistically significant differences between the two particle formulations at days 3 and 10. This
temporal analysis suggests that monitoring of cathepsin activity is useful in detecting the anti-
inflammatory effect of controlled-release therapeutics in the early phase of host response.
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3.4.2.2. Time-evolution of cellular infiltration
To understand how the temporal dynamics of in vivo cathepsin activity was related to time-
dependent cellular infiltration between the implanted microparticles, we also performed standard
histological analysis of excised tissues. Three mice were sacrificed at days 3, 10, 17 and 28
corresponding to the imaging time points in Figure 3.3. The excised polymer and surrounding tissues
were fixed, processed histologically and stained with Hematoxylin and Eosin. Figure 3.4A shows
representative tissue sections in which cell nuclei stained dark blue while collagen and cytoplasmic
materials stained pink.
Qualitative evaluation of samples collected on days 3 and 10 revealed that the central portions of
many polymer sections were detached during histology processing, while samples collected on days 17
and 27 remained intact. The non-homogenous properties of dermal tissue containing polymer particles
rendered it fragile during histological processing steps such as microtome sectioning and exposure to
various organic solvents such as xylene or alcohol[110]. In the earlier phase of the foreign body
response, cellular layers surrounding the implants might have been thinner and weaker; hence samples
on days 3 and 10 were more prone to dissociation from the dermal tissue. In the later phase of days 17
and 27, wound healing might have already resolved[3] with the formation pf strong fibrotic cell layers
holding the particles together; and thus the samples became more resilient during histology processing.
Despite the lower quality of samples collected on days 3 and 10, we observed neutrophils
infiltrating the spaces between polymer particles for both control and drug-loaded samples, and
minimal collagen deposition. At the later time points of days 17 and 27, extensive macrophage
infiltration and collagen deposition were oytbserved throughout the polymer sections of control
samples, while drug-loaded samples were free of cellular infiltration.
We used laser scanning cytometry to quantify the amount of inflammatory cells recruited to the
polymer injection sites according to established protocols[6-9, 14]. Figure 3.4B shows the extent of
cellular infiltration into each polymer spot, calculated as the ratio of total nuclei area to total polymer
cross-sectional area. The cellular coverage ratio was not statistically different for days 3 and 10, possibly
due to the sample detachment at earlier time points. However, the extent of infiltration of inflammatory
cells was significantly lower for drug-encapsulated polymers at later time points (days 17 and 27).
Together, the histological data and fluorescent imaging provided complementary information to confirm
that incorporation of dexamethasone decreased early protease activity and long-term cellular
infiltration in the host response to subcutaneously implanted materials.
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3.5. CONCLUSION
In this study, we have demonstrated the in vivo spatial and temporal host response to a
subcutaneously-implanted, controlled-release anti-inflammatory drug formulation. Microparticles with
low drug loading (1.3wt%) locally inhibited the activity of cathepsin enzymes from immune cells, while
high drug loading formulation (26wt%) resulted in systemic immunosuppression. We also learned that
incorporation of dexamethasone at a low loading (1.3wt%) attenuated the coverage of polymeric
microparticles by immune cell layers. Temporal monitoring of the drug effect confirmed that
incorporation of dexamethasone decreased early enzymatic activity and long-term cellular infiltration to
implanted materials. Although only one drug was tested in our study, this strategy may potentially be
extrapolated to investigate other existing drugs or to screen for new small molecules to expand the pool
of anti-inflammatory drugs. Various parameters influencing drug release kinetics, such as particle size
and polymer molecular weight, may also be explored. The ability to control the effects of anti-
inflammatory therapeutics on the host response should aid in the design of microsphere systems for
implanted biomedical devices including cardiovascular stents and glucose sensors.
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Figure 3.1: Effect of drug loading on the localization of anti-inflammatory properties.
(A) Injection pattern showing administration sites of PLGA particles without (0) and with (M)
dexamethasone. (B) Near-infrared fluorescent imaging on day 4 showed a high level of cathepsins at
the injection sites of control particles but localized inhibition of these enzymes at the sites of particles
with low drug loading. (C) Inhibition of cathepsin activity at all injection sites was observed on day 4
when particles with high drug loading were investigated. (D) In vitro release profiles of dexamethasone
showed a more pronounced initial burst release from microparticles with high drug loading.
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Figure 3.2: Anti-inflammatory drug attenuated coverage of implanted polymer by immune cell layers.
(A) Injection pattern showing administration sites of PLGA particles without (0) and with ( 0 )
dexamethasone. (B-C) Fluorescent imaging of the same mouse at different wavelengths showed near-
infrared signal of cathepsin activity (B) only at the sites of control particles and green polymer auto-
fluorescence (C) only at the sites of drug-loaded particles (D) Multiplex image combining in vivo
fluorescent signals at both wavelengths. (E) Fluorescent excitation-emission spectra of PLGA (50/50)
microparticles in solid state showed significant green autofluorescence but no near-infrared
autofluorescence. (F) Schematic illustration of the optical effect of immune cell layers. (G) Colored
photograph of the excised skin tissue showed that control polymer particles were compacted in
extensive fibrous tissue which reduced polymer auto-fluorescence at green wavelengths. The drug-
loaded microparticles remained flattened against the skin with minimal cellular coverage thus retaining
their auto-fluorescence. (H-1) Fluorescent imaging of ex vivo tissue at different wavelengths showed
near-infrared cathepsin activity (H) consistent with in vivo data. At the green wavelength condition (1), ex
vivo control particles also showed some auto-fluorescence of lower intensity than that of drug-loaded
particles.
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Figure 3.3: Quantitative temporal monitoring of cathepsin activity.
(A) Timeline of probe administration and imaging. (B) Near-infrared fluorescent images of one
representative mouse over a period of 28 days demonstrated the inhibitory effect of dexamethasone at
the earlier time points. All figures are of the same color scale. (C) Quantification of near-infrared
fluorescent signals from four replicates showed that cathepsin activity at the sites of control
microparticles was higher than drug-loaded microparticles at days 3 and 10. (**) indicates P<0.05 by the
Student's two-sample two-tailed t-test.
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Figure 3.4 Quantitative monitoring of cellular infiltration to the inter-particle spaces.
(A) Representative histology sections of excised tissues containing PLGA particles with and without
dlexamethasone from different mice sacrificed at various time points. Scale bar represents 50um for all
pictures. (B) Quantitative analysis of cellular infiltration by laser scanning cytometry showed the
inhibitory effect of dlexamethasone at later time points: days 17 and day 28. Extent of infiltration by
inflammatory cells was defined as the ratio of total nuclei area to total polymer cross-sectional area. (*
indicates P<0.05 by the Student's two-sample two-tailed -est.
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Figure 3.5: In vitro and in vivo fluorescent images of PLGA microparticles with different glycolide
monomer contents.
When imaged at the green wavelength configuration (excitation at 465nm, emission at 560nm),
microparticles fabricated from PLGA 50/50 show the strongest autofluorescent intensity, both in vitro
and in vivo. No significant signal was detected at the near-infrared imaging configuration used to detect
cathepsin activity (excitation at 605nm, emission at 720nm).
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Figure 3.6: Incorporation of dexamethasone did not alter the physical properties of the microparticles.
A) SEM images showed similar particle sizes and spherical morphology of control PLGA particles and
those encapsulating dexamethasone. All scale bars represent 10 prm. Adjacent fluorescent images
showed strong auto-fluorescence at visible wavelength and no detectable signal at near-infrared
imaging condition for both particle formulations. B) Similar fluorescent excitation and emission spectra
of PLGA microparticles with and without dexamethasone.
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CHAPTER 4 - ANTI-INFIAMMATORY DRIJGS FOR IMPROVED EFFICACY
OF ENCAPSUIATED ISUl7TS
The content of this chapter constitutes a manuscript to be submitted for peer-reviewed journal
publication and has also been incorporated in whole or in part in the following patent applications.
Anderson D.G, Langer R, and Dang TT. "Hybrid Microcapsules containing islets and anti-
inflammatory drugs for diabetes therapy". U.S.S.N. 61/444206, filed on Feb. 2011.
Anderson D.G, Langer R, and Dang TT. "Hydrogel-encapsulated cells and anti-inflammatory
drugs". U.S.S.N. 13/400,382 and PCT/US2012/025806, filed on Feb 2012.
4.1. ABSTRACT
Host response to implanted biomaterials leads to the formation of fibrotic cell layers which can
impair essential functions of implantable medical devices. Anti-inflammatory drugs have the potential to
overcome this challenge and improve device durability. Herein, we performed in vivo subcutaneous
screening of several classes of small molecule anti-inflammatory drugs encapsulated in PLGA
microparticles in immunocompetent hairless SKH-1E mice. Using parallel non-invasive fluorescent and
bioluminescent imaging during the acute inflammation phase, we demonstrated that a glucocorticoid,
dexamethasone, most effectively inhibited the activities of inflammatory proteases while curcumin, a
polyphenol drug, decreased the presence of reactive oxygen species secreted by early immune cells.
These drugs also decreased subsequent cellular infiltration and fibrosis formation surrounding the
subcutaneously injected polymeric microparticles. Next, we designed hybrid alginate hydrogel
microcapsules co-encapsulating pancreatic rat islets and drug candidates identified from the
subcutaneous screening. The results demonstrated that curcumin effectively reduced fibrotic response
against encapsulated islets and improved glycemic control in a C57B6/J mouse model of chemically-
induced type I diabetes. Overall, our approach represents a promising strategy to identify effective anti-
inflammatory drugs for potential applications in a broad range of implantable medical devices and
encapsulated therapeutic cells.
4.2. INTRODUCTION
Implantable biomedical devices such as biosensors, stents, and encapsulated therapeutic cells offer
exciting potential to advance human health. However, during the implantation of a biomedical device,
tissue injury activates the inflammation cascade which leads to migration of inflammatory cells to the
surgery sites, release of cytokines and growth factors that promote cellular proliferation and protein
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synthesis as well was complement activation, blood clotting and fibrinolytic cascades [1]. If left
uncontrolled, this sequence of events can trigger the proliferation of fibroblasts which synthesize and
deposit extracellular matrix to form granulation scar tissues resulting in limited in vivo functionality and
longevity of implanted devices[5].
Immuno-isolated therapeutic cells is an example of technologies hindered by the host response
despite its potential to address many critical medical challenges such as neurodegegenerative diseases
and hormone or enzyme deficiencies [111]. Non-autologous cells are encapsulated in a semi-permeable
hydrogel membrane which prevents direct contact between transplanted donor cells and host immune
cells while allowing exchange of nutrients, oxygen and secreted therapeutic molecules [112]. For
instance, microencapsulated pancreatic islets can produce insulin to restore normoglycemia in diabetic
animal recipients without the need for exogeneous insulin administration[16, 113-116]. However,
despite encouraging results in various animal models, translation of preclinical results to clinical
outcome for diabetes management has remained elusive [17-19].
One factor implicated in the limited success of encapsulated islets is the host immune response
responsible for the functional impairment and limited survival of the transplanted islet grafts. Though
direct cell-to-cell contact is mitigated by the presence of the isolating hydrogel membrane, the host
immunological systems might still be able to attack the encapsulated islets via the secretion of soluble
inflammatory mediators [26, 117-119] and the development of long-term pericapsular overgrowth[88].
Early immune cells recruited to the injury sites after surgical implantation secrete soluble molecules
such as nitric oxide, free radicals or cytokines which have the potential to induce islet toxicity and early
islet mass loss [25, 26, 120, 121]. These inflammatory mediators can diffuse through the semi-
permeable hydrogel membrane and cause islet dysfunction or morphological disintegration in a dose-
dependent manner [26, 122-124]. Furthermore, subsequent recruitment of fibroblasts can also result in
formation of fibrotic cell layers and collagen deposition on the surface of transplanted microcapsules
[90, 125]. Such pericapsular overgrowth reduces oxygen and nutrient transport which in turn lead to
necrosis of the islet cores and eventual failure of the transplanted grafts [90, 126].
Administration of anti-inflammatory drugs has been proposed as a strategy to mitigate host
response and improve the stability of implantable biomedical devices [6, 27, 91, 93, 127]. Incorporation
of controlled-release formulations of potent glucocorticoids or anti-proliferative drugs have reduced
fibroblast proliferation and collagen deposition resulting in clinical applications of drug-eluting pace-
maker leads and stents as well as preclinical development of biosensors in animal models [28, 31, 128-
131]. However, similar attempts to utilize anti-inflammatory drugs in cell-based therapeutics have
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remained largely unsuccessful. Short-term systemic delivery of steroids and antifibrotic drugs can
transiently inhibit recruitment of inflammatory cells, reduce fibrosis formation or improve the protein
secretion function of the immuno-isolated cellular grafts [132-134]. Nonetheless, such systemic
administration of immunosuppressants also resulted in deleterious side effects such as increased insulin
resistance, opportunistic infection, and nephrotoxicity [135, 136]. Recent studies suggested that
temporary localized delivery of immunomodulating agents within the immediate vicinity of the
encapsulated cells can reduce the tissue response caused by the limited biocompatibility of the
encapsulating hydrogel membrane. Bunger et al reported that temporary release of encapsulated
steroid from empty alginate-poly-L-lysine microcapsules reduced fibroblast proliferation 4 weeks after
intraperitoneal transplantation in rats[21]. Others also claimed that biodegradable microparticles
containing an NSAID may be used to reduce pericapsular overgrowth on Alginate-Poly-L-Ornithine-
Alginate microcapsules[137, 138]. However, despite providing uselful information, all existing studies
have been limited to the use of only a few anti-inflammatory drugs to address the fibrotic response
resulting solely from the limited biocompatibility of the hydrogel materials itself. They were also short-
term studies and involved only nonfunctional empty capsules in non-diabetic animals. Thus, it is of great
interest to explore the larger reservoir of existing anti-inflammatory molecules and identify promising
drug candidates which can better support islet functionality and survival. It is also important to evaluate
the efficacy of such combination drug-islet systems in relevant animal models of diabetes.
In this study, we employed non-invasive imaging techniques to perform systematic in vivo
screening of several classes of small molecule anti-inflammatory drugs in immunocompetent SKH1E
mice. We successfully identified drug candidates which suppressed early inflammation markers such as
reactive oxygen species and inflammatory proteases in the acute phase of the host response to
subcutaneously injected biomaterial. Hybrid hydrogel microcapsules were subsequently designed to co-
encapsulate selected drugs and xenogeneic pancreatic islets for efficacy evaluation in a mouse model of
chemically-induced type I diabetes. We found that hybrid drug-islet capsules containing curcumin, a
naturally occurring polyphenol, were able to reduce pericapsular overgrowth and improve graft
function.
4.3. MATERIALS AND METHODS
4.3.1. Animal care and use
The animal protocol was approved by the local animal ethics committees at Massachusetts Institute
of Technology (Committee on Animal Care) prior to initiation of the study. Male SKH-1E hairless
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immunocompetent mice, aged 8-12 weeks, were obtained from Charles River Laboratories (Wilmington,
MA, USA). Male Sprague-Dawley rats, 200-250 g, also obtained from Charles River Laboratories, were
used as islet donors. Diabetic male C57B6/J mice (Jackson Laboratory,Maine,USA) were the recipients of
encapsulated islets. Diabetes was induced in C57B6/J mice via a research contract with Jackson
Laboratory, Maine, USA. Briefly, male C57B6/J mice, aged 6-8weeks, were subjected to multiple low-
dose intraperitoneal injections of streptozotocin (STZ) (Sigma Aldrich) at a daily dose of 50 mg/kg. 200ul
of STZ freshly dissolved in saline at a concentration of 5mg/ml was administered to each mouse daily for
a period of 5 consecutive days. Induction of diabetes was confirmed 10-14 days post STZ-
administration by the presence of hyperglycemia when fed blood glucose levels of these mice rose
above 300mg/dL for two consecutive daily readings. Most animals reached this criterion by day 10 after
STZ administration, and only those with stable hyperglycemia were used for subsequent transplantation.
The mice received from Jackson laboratory were housed under standard conditions with a 12-hour
light/dark cycle at the animal facilities of Massachusetts Institute of Technology, accredited by the
American Association of Laboratory Animal Care. Both water and food were provided ad libitum except
for the night before Intraperiotoneal Glucose Tolerance Test (IPGTT).
4.3.2. Fabrication and characterization of PLGA microparticles
Microparticles with or without a drug were prepared using a single-emulsion method with
biodegradable PLGA 50/50 (inherent viscosity of 0.95-1.20dl/g) from Lactel (Pelham, AL). Typically, a
5mL solution of PLGA dissolved in dichloromethane at concentrations of 40mg/ml and a predetermined
concentration of the desired drug, was quickly added to a 25mL solution of 1% (w/v) polyvinyl alcohol
and homogenized for 60s at 5000rpm (Silverson L4R, Silverson Machines Ltd., Cheshire, England). The
resulting suspension was quickly decanted into 75mL of deionized water and stirred for 30s prior to
rotary evaporation (Buchi Rotavap, Buchi, Switzerland) for 3min. The suspension was washed five times
by centrifugation at 3000rpm for 3min. The particles were collected by filtration using 0.2tm filter,
flash-frozen in liquid nitrogen, and lyophilized to dryness.
4.3.3. Subcutaneous injection of PLGA microparticles
Before subcutaneous injection of the PLGA microparticles, hairless immunocompetent SKH-1E mice
were kept under inhaled anesthesia using 1-4% isoflurane in oxygen at a flow rate of 2.5 L/min.
Lyophilized microparticles with or without encapsulated drug were suspended in sterile 0.9% (w/v)
phosphate buffered saline at a concentration of 50mg/mL. A volume of 100ptL of this suspension was
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injected subcutaneously via a 23G needle at each of the six spots on the back of each hairless
immunocompetent SKH-1E mouse.
4.3.4. Non-invasive fluorescent and bioluminescent imaging of SKH-1E mice
SKH-1E mice were started on a non-fluorescent alfalfa-free diet (Harlan Teklad, Madison, WI, USA)
three days prior to subcutaneous injections of microparticles and maintained on this diet till the desired
sacrifice time point for tissue harvesting. To monitor cathepsin activity, the imaging probe ProSense-680
(VisEn Medical, Woburn, MA, USA), at a concentration of 2 nmol in 150 ml of sterile phosphate buffered
saline, was injected into the mice tail vein. After 24 h, in vivo fluorescence imaging was performed with
an IVIS-Spectrum measurement system (Xenogen, Hopkinton, MA, USA). The animals were maintained
under inhaled anesthesia using 1-4% isoflurane in oxygen at a flow rate of 2.5 L/min. Whole-animal
near-infrared fluorescent images were captured at an excitation of 605 nm and emission of 720 nm and
under optimized imaging configurations. To monitor reactive oxygen species, a volume of 200ul of
Sodium Luminol (Sigma Aldrich) dissolved in PBS buffer at a concentration of 50mg/ml was injected
intraperitoneally to each mouse prior to imaging (dose of 500mg/kg). Ten minute after this injection, the
mouse was imaged under bioluminescent setting in the IVIS system. Data were analyzed using the
manufacturer's Living Image 3.1 software. Fluorescent images are presented in fluorescence efficiency
which is defined as the ratio of the collected fluorescent intensity normalized against an internal
reference to account for the variations in the distribution of incident light intensity. Regions of interest
(ROls) were determined around the site of injection. ROI signal intensities were calculated in total
fluorescent efficiency for fluorescence images and in photons per second for bioluminescent images.
4.3.5. Tissue retrieval and histology processing of subcutaneously injected PLGA
microparticles
At the desired time points, mice were euthanized via CO2 asphyxiation. The injected polymer and
one square centimeter area of full thickness dermal tissue surrounding the implant were excised, placed
in histology cassettes and fixed in 10% formalin overnight. Following fixation, the tissues were
dehydrated by transferring the cassettes to 70% ethanol solutions. The polymer particles with the
surrounding fixed tissues were embedded in paraffin and sectioned into samples of 5 pm thickness.
These samples were stained with hematoxylin and eosin (H&E) for histological analysis.
4.3.6. Isolation of rat pancreatic islets
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Male, Sprague-Dawley (SD) rats weighed 200-250g were intraperitoneally anesthesized with 400ul
mixture of Ketamine (60-80 mg/kg) and Xylazine (5-10 mg/kg). A laparotomy was then performed and
the pancreas was exposed. The common bile duct was ligated at its entrance into the duodenum,
cannulated proximally with siliconized tubing (0.023" ID, 0.038" OD, Intramedic) and injected with 8ml
of M199 medium (Invitrogen) containing 0.152mg/ml rodent collagenase Liberase TL ( Roche). The
animal was then sacrificed, and the pancreas was carefully dissected from the surrounding tissue and
incubated in a 37'C water bath for 17-23 minutes. Enzymatic digestion was stopped by adding 15ml of
cold M199 medium supplemented with 10% fetal bovine calf serum (Invitrogen). The tissue was
subsequently washed three times and filtered through a 400um sieve. A density gradient utilizing
Histopaque 1077 (Sigma Aldrich) was used to separate the islets from exocrine tissue, and was followed
by gravity sedimentation in M199 medium with 10% fetal bovine serum. Isolated islets were then hand-
picked under a stereomicroscope, collected into a Petri dish and cultured overnight at 370C, 5% C02, at
a density of 2500 islets/10ml in 35ml of RPMI-1640 medium supplemented with 10% fetal bovine serum
(FBS), 100 units/mI penicillin and 100 pg/ml streptomycin (Invitrogen).
4.3.7. Fabrication of hybrid alginate microcapsules co-encapsulating drug and islets
Alginate with high gluronic acid content SLG20 (Novamatrix, FMC Polymer, Drammen, Norway) was
dissolved in sterile 0.9% (w/v) NaCl to give a solution of 1.5% (w/v). To prepare hybrid drug-islet
capsule, 1.5%(w/v) alginate was mixed with curcumin (Sigma Aldrich) at 1.0mg/ml or with
dexamethasone (Sigma Aldrich) at 2mg/ml and stirred for 4 days to ensure that the drug is
homogenously dispersed. During this mixing period, the curcumin-alginate mixture was wrapped in
aluminium foil to avoid light exposure which might oxidize this drug. One days after islet isolation, islets
were washed twice with Ca-free KREBS buffer (135mM NaCl, 4.7mM KCI, 25mM HEPES, 1.2mM KH2PO4,
1.2mM MgSO 4) and mixed with the alginate suspension with or without dispersed drug. Microcapsules
encapsulating islets with or without drugs were produced using an electrostatic droplet generator by
extrusion of the islet-alginate suspension through a 22G needle at a volume flow rate of 0.155ml/min
and a voltage of 6kV into a cross-linking bath of 20 mM BaCl 2 solution. Encapsulated islets were then left
to cross-link in this solution for 5 minutes before being collected into a 50ml Falcon tube. The capsules
were subsequently washed four times with HEPES buffer (132mM NaCl, 4.7mM KCI, 25mM HEPES,
1.2mM MgCl 2) and two times with RPMI-1640 medium supplemented with 10% Fetal Bovine Serum and
100units/ml penicillin and 100 pg/ml streptomycin (Invitrogen). The final microcapsule diameter was in
the range of 500-600 um.
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4.3.8. Transplantation of encapsulated islets into STZ-induced diabetic C57B6/J mice
Xenogeneic transplants of encapsulated rat islets into diabetic C57B6/J mice recipients were
performed to examine the reversibility of diabetes. One day after isolation from Sprague-Dawley rats,
islets were encapsulated with or without an anti-inflammatory drug (curcumin or dexamethasone).
Shortly thereafter, islet-containing capsules were sampled in quadruplicates; and the total islet number
was counted. Each aliquot of the capsules suspended in culture media were prepared to contain 2501E.
Capsule aliquots were kept on ice and washed twice in sterile 0.9wt% sodium chloride solution before
the surgery. They were then transplanted intraperitoneally via a lapratomy procedure with a 5-10 mm
abdominal incision into diabetic C57B6/J mice kept under 1-4% isofluorane-in-oxygen anaesthesia.
Typically, each mouse received 2501E (post-encapsulation islet count) in a total capsule volume of 500ul.
4.3.9. Blood glucose monitoring and Intraperitoneal Glucose Tolerance Test
4.3.9.1. Daily blood glucose monitoring:
Animal blood glucose was determined between 9-11am using a portable glucometer (Clarity Plus).
Blood was taken from a tail vein with the total volume drawn per collection not exceeding 5ul.
4.3.9.2. Intraperitoneal glucose tolerance test (IPGTT):
C57B6/J mice were fasted overnight (6pm-9am) the night before IPGTT. On the day of the glucose
challenge, each animal was injected intraperitoneally with 400ul of 10%(w/v) of glucose in sterile 0.9%
NaCl, and its blood glucose was taken at 15, 30, 60,75, 90,105 and 120 minutes post-injection. Diabetic
and non-diabetic C57B6/J mice were also included as control animals.
4.3.10. Retrieval of transplanted capsules from the intraperitoneal cavity
Sixty days after transplantation of islet-containing capsules, the mice were sacrificed by carbon
dioxide asphyxiation. A lapratomy was performed to expose the abdominal cavity and capsules were
retrieved by an abdominal lavage with HEPES buffer. The abdominal cavity was examined closely to
identify remaining capsules, which if found were gently removed using a pair of atraumatic tweezers.
The retrieved capsules were subsequently washed several times in HEPES buffer and imaged at 2x
magnification using an EVOS microscope (AMG). The internal organs of each mouse were examined
carefully to ensure that all capsules were retrieved. Finally, capsules were transferred into a 1.5ml
Eppendorf tube, and frozen at -20 0C for future analysis.
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4.3.11. Quantification of fibrosis by DNA fluorescent staining
50ul of the retrieved capsules were transferred to each well of a 24well Millicell* cell culture insert
(Millipore) using wide-orifice pipette tips (Fisher Scientific, Pittsburgh, PA, USA). The capsules were
incubated at 370C for 45minutes in 800ul of 0.001mg/mi Hoersch 33342 dye (Invitrogen) prepared from
dye stock solution by dilution with HEPES buffer. Afterwards, these capsules were washed four times
with HEPES buffer. The capsules were contained in the upper Millicell* insert which had a porous
bottom membrane separating the capsules from the lower container well. The use of a porous insert
helped to avoid the loss of capsules during washing steps as washing buffer could be removed by
aspiration from the lower well or draining away from the upper insert by placing a Kimwipe below the
porous membrane. All capsules were subsequently transferred in 300ptl of HEPES buffer into a black 96
well plate (Greiner BioOne). Finally, fluorescent signals from the stained capsules were obtained using a
Tecan UV-VIS absorbance plate reader at with the excitation and emission wavelengths of 350nm and
460nm respectively.
4.3.12. Statistical analysis
All values were averaged and expressed as the mean ± standard error of the mean. Fluorescent or
bioluminescent signals from injection sites of drug-loaded microparticles and control microparticles
were compared using the Student's two-tailed two-sample t-test. Comparison of the blood glucose
levels and quantified DNA fluorescence signals were performed using one-way ANOVA with Fisher's LSD
post-hoc test. P-values less than 0.05 were considered significant.
4.4. RESULTS
4.4.1. In vivo subcutaneous screening of small molecule anti-inflammatory drugs
We first sought to evaluate the effects of anti-inflammatory agents on the early cellular dynamics
of host response to implanted biomaterials by in vivo subcutaneous screening of 16 small molecule
drugs (Table 4.1). These agents belong to several different classes of drugs whose efficacies in inhibiting
inflammation have been reported such as steroidal [99, 102, 139, 140] and non-steroidal
immunosuppressants [141], non-steroidal anti-inflammatory drugs (NSAIDs) [98, 102, 142], and
naturally occurring polyphenols [143]. Each drug was encapsulated in poly-lactic-co-glycolic
microparticles at three different theoretical loadings (5,10,15wt%) by a water-in-oil emulsion
method[100]. The subcutaneous space was selected for initial screening of the drugs as it is the implant
site that induces aggressive host response, hence providing a stringent threshold to identify effective
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drug candidates [144]. The subcutaneous site also facilitates microparticles injection and monitoring of
the host response by non-invasive imaging techniques [104, 145-147]. In the subcutaneous screening,
we employed a platform of non-invasive in vivo imaging which allows analysis of multiple particle
formulations injected into the same mouse[145]. Each formulation of drug-loaded microparticles was
injected in triplicate on the dorsal side of each mouse. Control particles without encapsulated drug were
similarly administered at the three remaining sites on the same mouse. Two markers of inflammation
secreted by early immune cells, namely cathepsin enzymes and reactive oxygen species (ROS), were
monitored using a combination of non-invasive fluorescent and bioluminescent imaging techniques
following procedures previously reported by our laboratory [104, 145-147]. Cathepsin enzymes, a class
of inflammatory proteases, were detected by a fluorescent-activated probe whose signal correlates with
the presence of neutrophils in the acute inflammatory response [104, 147]. Luminol was oxidized by ROS
emitting bioluminescent signal which can be used to assess host response to implanted biomaterials
[147]. Relative fluorescent or bioluminescent signal was calculated as a ratio of the signal from the drug-
loaded microparticles to that from the control particles in the same mice (n=6 replicate injections in 2
mice for each drug-loaded particle formulation). A lower relative signal indicates a lower activity of each
inflammation marker and a value below 1.00 corresponds to a decreased activity compared to the
control formulation.
Figure 4.1 summarizes the imaging data from the in vivo screening of all drug formulations on day 3
after the microparticles were subcutaneously injected. Analysis of the results revealed several trends
regarding the effects of the drugs on the activitives of cathepsin enzymes and reactive oxygen species.
Fluorescent imaging data (Figure 4.1A) showed that several steroidal agents such as dexamethasone,
hydrocortisone, flurocortisones and prednisolone suppressed the activity of cathepsin enzymes while
NSAIDs and other non-steroidal immunosuppressants generally did not. Curcumin caused a slight
decrease in cathepsin activity while resveratrol did not, though both drugs belong to the same class of
polyphenol compounds. In contrast, bioluminescent data (Figure 4.1B) illustrated that most drugs did
not cause any reduction in ROS activity, with the exception of curcumin, sunlindac, rapamycin and
flurocortisone. When arranged in descending order of relative imaging signal (Supplementary Figure
4.6), dexamethasone and curcumin formulations were identified as most effective in suppressing
cathepsin and ROS activities respectively.
4.4.2. Effect of selected drugs on the subcutaneous cellular dynamics and fibrosis
formation
57
To further examine the effects of promising drug candidates, temporal monitoring of the activities
of early immune cells was performed for three selected drug formulations over an extended time
period. A higher number of injection replicates (n=15 injections i.e 3 injections of each drug formulation
in 5 different mice) was carried out for better statistical significance. Dexamethasone 5wt% and
Curcumin 15wt% were chosen to represent the drug formulations most effective in decreasing cathepsin
activities and reactive oxygen species respectively. Ketoprofen 15wt% was selected to represent the
drug formulation with no effect on both types of inflammation markers. After subcutaneous injection of
the microparticles in to SKH1E mice, the animals were imaged daily for reactive oxygen species during
first 7 days and for cathepsin activities on days 3, 9, 15, 21 and 28. Quantification of the imaging signals
(Supplementary Figure 4.7) showed that, for the polymer particles without drugs, ROS activity was the
highest during the first 3 days while cathepsin activity was the highest at days 3 and 9. Both signals
decreased significantly at later time points.
Figure 4.2A shows the injection pattern of the PLGA microparticles with and without drugs. Figure
4.2B-D shows bioluminescent images of representative mice at the peak of ROS activity on day 2.
Quantification of the peak ROS signals (Figure 4.2E) confirmed the observation from the subcutaneous
screening that curcumin significantly reduced ROS activity at the implant sites (p<0.01) by approximately
three fold. Dexamethasone also caused a slight decrease (p<0.05) while ketoprofen did not affect ROS
production in the host response to PLGA particles. Representative fluorescent images at the peak of
cathepsin activity on day 9 are shown in Figure 4.2F-H. Quantification of these fluorescent signals on day
9 (Figure 4.21) showed that dexamethasone reduced this protease activity significantly (p<0.0001) by
approximately two-fold. Curcumin caused a less significant decrease (p<0.01) while ketoprofen did not
affect cathepsin activity. The differences that exist in the fluorescent and bioluminescent signals, can be
attributed to the different cellular products measured[147]. This may be resultant of the different
effects the drugs exert on the different cell-type populations present at the implant sites as well as their
activities in response to the drug-PLGA formulation.
To monitor the cellular infiltration into the inter-particle spaces of the injected microparticles, we
performed histology analysis of excised tissues from mice sacrificed at different time points up to 28
days. Figure 4.3 shows representative Hematoxylin and Eosin sections of tissues with control particles
and particles containing dexamethasone, curcumin and ketoprofen. For the control samples (Figure
4.3A-E), cellular infiltration and collagen deposition followed the typical time-course of the host
response as reported in previous studies [2, 3]. In the early phase, neutrophils occupied the spaces
between the microparticles while at the later time points, extensive macrophage infiltration and
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collagen deposition were observed throughout the polymer sections of the control samples. In contrast,
the samples containing dexamethasone-loaded particles (Figure 4.3F-J) were almost free of immune
cells and collagen for at least four weeks, except for a few cells present at the edges of the samples.
Curcumin also minimized the host response; samples containing this drug remained free of cellular
infiltration for up to 2 weeks (Figure 4.3K-M). After this time point, gradual infiltration of macrophages
to curcumin-loaded particles was observed from partial cellular coverage at day 15 to complete
coverage on day 28 (Figure 3N-O). However, ketoprofen did not inhibit the host response; all samples
containing this drug showed similar pattern of cellular and collagen infiltration compared to the control
samples (Figure 4.3P-T)
4.4.3. Improved glycemic control by alginate microcapsules co-encapsulating drug
and islets in diabetic mice
We hypothesized that delivery of a suitable anti-inflammatory drug directly from the microcapsules
containing donor islets can mitigate the harmful impact of early inflammatory cells and reduce long-
term fibrosis to achieve better islet functionality and survival. Based on the results from subcutaneous in
vivo screening, we examined the potential of top performing drugs in reducing the host response to
encapsulated pancreatic islets and improving their efficacy in diabetes therapy. Hybrid drug-islet
microcapsules co-encapsulating curcumin or dexamethasone with pancreatic islets isolated from
Sprague-Dawley rats were fabricated using an electrostatic droplet generator. Drug molecules were
homogeneously dispersed in 1.5wt% SLG20 alginate at a concentration of 1mg/ml or 2mg/ml for
curcumin or dexamethasone respectively. These drug concentrations were determined as optimal from
preliminary experiments with different drug loadings ranging from 0.3 to 3.0mg/mI. Due to each drug's
hydrophobic nature, higher drug concentrations were avoided as these conditions often resulted in a
large fraction of defective capsules with non-uniform sizes, non-spherical shape and undesirable
irregularities which can potentially lead to increased attachment of immune cells [88, 90, 148, 149}.
Figure 4.A-C shows the hybrid drug-islet capsules with uniform spherical shape and diameters of 500-
600um. Dexamethasone-loaded capsules appeared white while curcumin capsules appeared yellow due
to the intrinsic color of each drug.
To evaluate the in vivo efficacy of the hybrid drug-islet capsules, we utilized a xenogeneic mouse
model of chemically-induced type I diabetes with marginal islet mass transplantation [150, 151]. Our
objective is to determine whether the hybrid drug-islet capsules improve graft survival and function with
a minimal amount of transplanted islets. Male C57B6/J mice were intraperitoneally administered with
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streptozotocin (STZ) to destroy the native beta cells of their pancreas and induce a state of insulin-
dependent hyperglycemia[152]. The amount of encapsulated Sprague-Dawley rat islet tissue that would
marginally cure these STZ-diabetic C57B6/J mouse recipients was determined in preliminary transplant
experiments with different islet doses (Supplementary Figure 4.9). All mice transplanted with 75 and 150
islet equivalents (IE, an islet with a diameter of 150um containing approximately 1500-2000 cells[153,
154]) did not reversed diabetes but animals with 3001E were able to reverse diabetes for more than 2
weeks. A marginal islet mass of 250 IE was chosen for evaluation of the hybrid drug-islet capsules. Two
types of hybrid capsules, each containing curcumin or dexamethasone, and control capsules which
contain only the islets were transplanted into STZ-induced diabetic mice for comparison (n=6-7). All
transplants achieved normo-glycemia within the first 11 days. Over the two months post-
transplantation, capsules with curcumin achieved better glycemic control compared to control capsules
and capsules with dexamethasone as shown in Figure 4.4D. During the time period of day 29 to day 60,
the blood glucose level of mice with curcumin capsules were statistically lower than that of the control
mice. However, the difference between blood glucose levels of the animals transplanted with
dexamethasone-loaded capsules and control capsules was not significant. The average blood glucose
level of the curcumin-loaded capsules only rose above 200mg/dl after day 30 while the failure of the
islet grafts in the control and dexamethasone-containing capsules occurred earlier, at approximately
days 15 and 21 respectively.
In addition, intraperitoneal glucose tolerance tests (IPGTT) showed that the islets co-encapsulated
with curcumin remained responsive to glucose after 2 months (Figure 4.4E). After overnight fasting (at
time point of 0 min), mice with curcumin-loaded capsules had lower fasting blood glucose levels which
are similar to the values for non-diabetic mice (p>0.438) while animals with the control islet capsules
(p<0.001) and dexamethasone-loaded capsules (p<0.05) had significantly higher fasting blood glucose
compared to the non-diabetic mice. During the two-hour IPGTT, the blood glucose levels of all diabetic
mice transplanted with control or hybrid capsules reached a peak at 30 minute which is a slight delay
compared with a peak at 15 minute in non-diabetic mice. At each time point, significantly lower blood
glucose levels were observed in the mice that received curcumin-loaded capsules compared to the
animal group with control islet microcapsules (p<0.01 at all time points till 105 min and p<0.05 at 120
min). The IPGTT data indicated that islets co-encapsulated with curcumin were able clear glucose more
effectively than the control islet capsules. Dexamethasone-loaded capsules did not significantly improve
the glucose clearance compared to the control capsule.
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4.4.4. Reduced fibrotic overgrowth on explanted hybrid drug-islet capsules
We also evaluated the effect of the anti-inflammatory drugs in reducing the fibrotic overgrowth
on microcapsules encapsulating islets. Previous studies have attempted to quantify the extent of
pericapsular overgrowth on explanted encapsulated islets. Each sample of explanted capsules was
observed by an investigator, and assigned a numerical score depending on the estimated percentage of
capsules with pericapsular overgrowth [118, 126, 155-157]. However, these traditional approaches
remained semi-quantitative, time-consuming and potentially subjective, depending on the individual
performing the assessment and the quality of the images captured for the samples [26]. To overcome
these limitations, we developed a new method for rigorous quantification of fibrotic overgrowth on
explanted capsules. The capsules were stained with Hoestch 33342 dye whose fluorescence was
enhanced when bound to the DNA of the immune cells covering the capsule surface. Measurement of
this fluorescence signal provided a quantitative assessment of the number of cells attached to the
capsules (Supplementary Figure 4.10).
The new DNA-staining method was used to assess fibrotic overgrowth on encapsulated islets
which were retrieved from diabetic mice by peritoneal lavage on day 60 after transplantation (Figure
4.5). These animals were the same mice that received control and hybrid drug-islet capsules whose
effects on glycemic control were previously shown in Figure 4.4. Figures 4.5A-C show the fluorescent
images of three types of explanted capsules after DNA staining while figures 4.5D-F are the phase
contrast images of the same capsules. Fibrotic capsules appeared darker in the phase contrast images
and showed enhanced blue emission in the fluorescent images due to the binding of Hoestch 33342 dye
to the DNA of fibrotic cell layers covering the surface of the capsules. In contrast, capsules without
pericapsular overgrowth appeared transparent in the phase contrast images and gave no fluorescent
signal. Figure 4.5J shows the quantified fluorescence signals from hybrid drug-islet capsules containing
curcumin or dexamethasone in comparison with control capsules without any drug. Curcumin
significantly reduced fibrosis compared to the control capsules while dexamethasone did not.
Figure 4.5G-1 showed representative histological cross-sections of explanted capsules embedded
in agar hydrogel and stained with Hematoxylin and Eosin. The histology data confirmed the presence of
immune cellular layers on the surface of retrieved control and dexamethasone-loaded capsules. Some
dark purple circular cross-sections of the alginate capsules have been lost during histological processing
but the pericapsular overgrowth on fibrotic caspsules remained as exterior rings comprising of a single
or several cell layers.
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4.5. DISCUSSION
Our in vivo subcutaneous screening demonstrated that several but not all steroidal
glucocorticoids were able to suppress, cathepsin activities in the early host response to implanted PLGA
microparticles. Steroidal glucocorticoids act through numerous genomic and non-genomic pathways to
block the synthesis of metabolites which are important mediators for cytokine production, leukocyte
recruitment and activation in early inflammation [99, 102, 139, 140]. Though these drugs have been
assumed to act through similar general mechanisms, the detailed pathways of their action are still not
comprehensively understood [99]. In addition, the ability of each drug to suppress immune cells and
hence their secretion of inflammatory proteases might also vary depending on its individual
pharmacodynamic properties, glucorticoidal potency or other factors such as drug loading and
hydrophobicity which can influence its controlled release kinetics. Among these glucocorticoids, the
most effective drugs in suppressing cathepsin activity such as dexamethasone, flurocortisones, and
prednisolone appear to correlate with the highest glucocorticoidal potency [102].
ROS are oxygen-derived free radicals produced by several types of immune cells such as
neutrophils and macrophages. They are activators of transcription factors Nk-kB mediating cell and
tissue injury during inflammation[158-161] and also play a role in degradation of aliphatic polyesters
[162]. Any inhibitory effect of steroidal glucocorticoids on ROS activity is not apparent from the
bioluminescent screening data, except for dexamethasone, the most potent steroid, which has
previously been reported to be ROS-inhibiting by Selvam et al [163]
Polyphenols are a large family of naturally occurring plant products that are widely distributed in
fruits, vegetables, nuts, seeds, flowers and bark [164]. These compounds are reported to be responsible
for the blockage of the transcription factor NF-kB which is required for transcription of genes involved in
the inflammatory responses [143, 165]. In our study, curcumin significantly inhibited ROS activity and
cathepsin enzymes, albeit to a lesser extent. Histology analysis of curcumin-loaded PLGA microparticles
excised from SKH1E mice during the first two weeks indicated that the recruitment of early
inflammatory cells to these samples was effectively inhibited. Therefore, we could confirm that the
reduced bioluminescent signal for curcumin-loaded microparticles resulted from the ability of this drug
to inhibit cellular migration in the subcutaneous host response. Surprisingly, resveratrol did not reduce
ROS or cathepsin expression though these two drugs belong to the same class of compounds and have
been assumed to have similar mechanism of action[166-168].
Non-steroidal anti-inflammatory drugs (NSAIDs) bind to the hydrophobic active sites of
cyclooxygenase (COX) enzymes to inhibit the COX-mediated generation of proinflammatory molecules
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and hence limit the extent of inflammation, fever and pain [98, 102, 142]. Our study demonstrated that
locally released NSAIDs, especially ketoprofen, were not effective in suppressing both cathepsin and ROS
in the subcutaneous host response to implanted PLGA microparticles. This finding was surprising given
numerous existing studies reporting the effectiveness of NSAIDs in alleviating inflammation when
administered systemically [98, 102, 142] and a limited number of studies claiming the efficacy of their
locally administered formulations in reducing fibrosis formation [6, 137]. However, Schneider et. al. has
also demonstrated that when systemically administered, dexamethasone but not diclorofenac, an
NSAID, can modulate the host response to improve the survival of encapsulated myoblasts [132]. These
discrepancies can potentially be explained by the difference in dosages or the pharmacodynamic
properties of controlled-release NSAID formulations versus systemic administration of the same
compounds.
In addition, other non-steroidal immunosuppressant drugs such as tacrolimus and cyclosporine
whose potent properties result primarily from inhibition of T and B lymphocyte activation [141] did not
effectively inhibit ROS or cathepsin enzymes. This finding is not surprising because the cell populations
impacted by these drugs belong to the adaptive immune systems while the subcutaneous host response
mainly involved innate immune cells such as neutrophils, macrophages and fibroblasts [2, 3, 169].
Furthermore, T and B lymphocytes are not known to produce ROS or capthepsin and hence the effects
of these drugs on these adaptive immune cells, even if present, were not likely to be captured by our in
vivo imaging assays.
Dexamethasone and curcumin, the most effective anti-inflammatory agents identified from the
subcutaneous screening, were incorporated in hybrid drug-islet alginate capsules to mitigate fibrotic
response against the transplanted capsules containing pancreatic rat islets. Fibrosis or pericapsular
overgrowth has been implicated in the limited long-term survival of encapsulated islets in various animal
models [24, 26, 126, 156, 170]. Cellular and collagen deposition on the surface of transplanted
microcapsules has been reported to result in delayed insulin secretion in response to plasma glucose
fluctuations, reduced nutrient transport and subsequent decrease in graft viability and function [24,
171, 172]. In our current capsule design, curcumin reduced fibrotic overgrowth, improved graft survival
and function while dexamethasone did not. However, in the subcutaneous screening with PLGA
microparticles, dexamethasone was able to inhibit cellular infiltration for a longer time period than
curcumin. The effects of these two drugs on the encapsulated islet system did not correlate directly with
their impact on the subcutaneously injected PLGA microparticles. Several major differences in these
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two systems might be accountable for this discrepancy such as the encapsulating polymers, the
administration sites, and the effects of the drugs on the encapsulated therapeutic cells.
Alginate is a non-degradable hydrophilic hydrogel [173, 174] while PLGA is a biodegradable
hydrophobic polymer [2, 175-177]. The mechanism of drug release from the PLGA particles involves
both passive drug diffusion out of the polymer pores and drug release due to the degradation of the
polymer matrix [178, 179]. In contrast, only the diffusional mechanism influences the drug release
kinetics from the non-degradable alginate capsules. In the intraperitoneal space, the close proximity
between the drug-loaded alginate microcapsules and the intestinal vasculature could facilitate faster
clearance of the drug and their metabolites resulting in more rapid drug diffusion outside of the alginate
capsules. The less hydrophobic dexamethasone could have diffused into the intraperitoneal space faster
than curcumin and thus the reservoir of encapsulated dexamethasone was exhausted more rapidly
resulting in a loss of its inhibitory effect on the attacking immune cells. Residual curcumin remained in
the alginate hydrogel capsules for a longer period of time (Supplementary Figure 4.11) and thus
prolonged its effectiveness in mitigating the fibrotic response, possibly due to its lower aqueous
solubility (0.6ig/ml at room temperature) [180] compared to that of dexamethasone (1mg/mi at 37 0C)
[181]. In the subcutaneous space, the diffusion and absorption of a drug and its metabolites into the
surrounding vasculature is less effective than into the intraperitoneal space [182, 183]. There is
potentially less significant difference between the release kinetics of dexamethasone and curcumin, so
the potency in inhibiting cellular filtration is more dominant factor compared to drug solubility or
hydrophobicity resulting in dexamethasone being more efficacious subcutaneously.
In addition, the incorporated drugs also have varying effects on the encapsulated islets.
Dexamethasone and other potent synthetic steroids have been reported to have diabetogenic effect
and inhibit insulin secretion from islets [34]. Even though potent glucocorticoids might be effective in
mitigating the host response, they might not be efficacious for incorporation in cell-based therapeutics
as it might adversely affects cell viability and function [35, 36]. In contrast, several studies have reported
that due to its anti-oxidant capacity, curcumin can protect islets against pro-inflammatory cytokines in
vitro, prevent the progression of diabetes in vivo and is effective in islet cryopreservation [184, 185].
These protective effects of curcumin on islets could be accountable for its ability to maintain better
glycemic control and graft survival compared to dexamethasone in the hybrid drug-islet alginate
microcapsules. Our findings suggested that the subcutaneous screening approach is valuable in
narrowing the choices of promising anti-inflammatory drugs; however, the efficacy of each drug
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candidate for a desired application still needs to be further evaluated in medically relevant context to
take into account other application-specific factors.
Several strategies could potentially be explored in future studies to improve the efficacy of the
drug-islet hybrid capsules. Firstly, improved release kinetics of less hydrophobic anti-inflammatory
agents such as dexamethasone can potentially be achieved by covalently attachment of the drug to the
alginate hydrogel via a degradable linking moiety such as an ester group or a hydrazide group.
Hydrolysis of the linking ester groups in vivo can release dexamethasone at a slower rate over an
extended period of time to match the cellular recruitment timeline of the host response. Secondly, a
combination of both dexamethasone and curcumin or other combinations of anti-inflammatory agents
might have the potential to act synergistically in suppress immune responses against non-self materials.
However, in this case, the effects of potential overdose, systemic toxicity or drug interference must be
carefully considered. Thirdly, a next generation of hybrid drug-islet capsules can be designed to have a
core-shell structure in which the cells are encapsulated in the inner core and the anti-inflammatory
drugs are encapsulated within an external shell. In this future design, the drug and the therapeutic cells
will be compartmentalized in two different layers within the hydrogel capsules. Confining the drug to
the surface of the hydrogel capsules facilitates outward drug diffusion, maximizes drug interaction with
immune cells, and minimizes its interference with the therapeutic cells inside.
4.6. CONCLUSION
In this study, we performed comparative characterization of a variety of small molecule anti-
inflammatory drugs utilizing both non-invasive in vivo imaging and end-point histology. Dexamethasone
and curcumin were most effective in inhibiting the activities of early inflammatory proteases and
reactive oxygen species as well as minimizing cellular infiltration and collagen formation in the
subcutaneous host response to implanted PLGA microparticles. Application of this finding to immuno-
isolated islets for the treatment of type I diabetes showed that curcumin was able to improve glycemic
control and mitigate the formation of pericapsular overgrowth on alginate microcapsules transplanted
into chemically-induced diabetic mice. Therefore, in vivo screening of the anti-inflammatory agents in
the subcutaneous space is a useful strategy for rapid identification of promising small molecule drugs
which can minimize host response to implanted biomaterials. We believe that our findings have
potential applications in a broad range of implantable medical devices and cell transplantation therapies
for the treatment of neurodegenerative diseases and hormone deficiencies.
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Table 4.1: Small molecule anti-inflammatory drugs investigated in the in vivo subcutaneous screening.
Different classes of compounds including naturally-derived polyphenols, NSAIDs, non-steroidal
immunosuppressants and steroidal glucocorticoids were screened in hairless immunocompetent SKH-1E
mice. For most compounds, several formulations with different percentages of drug loading were
tested.
Curcumin 15, 10 5
Resveratrol 15
Ketoprofen 15
Diclorofenac 15
Sunlindac 15
Piroxicam 15
Celecoxib 15, 10, 5
Polyphenol
Polyphenol
NSAIDs (COX-1 inhibitor)
NSAIDs (COX-1 inhibitor)
NSAIDs (COX-1 inhibitor)
NSAIDs (COX-1 inhibitor)
NSAIDs (COX-2 inhibitor)
Rapamycin 15, 10, 5 Non-steroid immunosuppressant
Tacrolimus 15, 10, 5 Non-steroid immunosuppressant
Cyclosporin 15, 10, 5 Non-steroid immunosuppressant
Dexamethasone 10, 5, 2 Steroidal glucocorticoid
Fludrocortisone 15, 10, 5 Steroidal glucocorticoid
Methylprednisolone 15, 10, 5 Steroidal glucocorticoid
Prednisolone 10, 5 Steroidal glucocorticoid
Prednisone 15, 10,5 Steroidal glucocorticoid
Hydrocortisone 15, 10, 5 Steroidal glucocorticoid
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curumbi,10%
curcuman,S%
Resveratrol,1s%
Ketopron, 1s%
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Figure 4.1: In vivo subcutaneous screening of anti-inflammatory drugs encapsulated in PLGA
microparticles.
A) Activity of cathepsin enzymes was quantified using Prosense 680, a fluorescence-activated imaging
probe. B) Presence of reactive oxygen species was quantified using luminol which emits
bioluminescence when oxidized by ROS. Relative fluorescent or bioluminescent signal was calculated as
a ratio of the signal from the drug-loaded microparticles to that from the control particles in the same
mice. Each data point represents the average signal ± s.e.m (n=6 replicate injections).
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Figure 4.2: Effects of selected drugs on the peak activities of cathepsin enzymes and ROS in the
subcutaneous host response to PLGA microparticles.
A) Injection pattern of the PLGA microparticles without (O) and with drugs (0). B-D) Bioluminescent
images of representative mice on day 2 at the peak of ROS activity. E) Quantification of the
bioluminescent signals on day 2 (n=15 replicate injections) showed that curcumin significantly reduced
ROS activity at the implant sites. Dexamethasone also caused a slight decrease while ketoprofen did not
affect ROS production. F-H) Fluorescent images of representative mice on day 9 at the peak of cathepsin
activity. I) Quantification of the fluorescent signal on day 9 (n=15 replicate injections) showed that
dexamethasone reduced this protease activity significantly. Curcumin caused a less significant decrease
while ketoprofen did not affect cathepsin activity. Each data point represents the average signal ± s.e.m.
(*, **, *** denotes p<0.05, 0.01, 0.0001 respectively).
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Figure 4.3: Histology analysis of subcutaneously injected PLGA microparticles with and without drugs
excised from SKH-1E mice at different time points over a period of 28 days.
Scale bar represents 50um for all images. Yellow arrows indicate areas with minimal infiltration of
immune cells. A-E) Samples with the control microparticles showed the typical time-course of the
subcutaneous host response with neutrophil infiltration at the earlier time points (A-B) and macrophage
recruitment as well as collagen deposition at the later time points (C-D). F-J) Samples containing
dexamethasone showed minimal infiltration of immune cells or formation of collagen matrix throughout
the 28 day duration. K-0) Samples containing curcumin remained free of immune cells and collagen
matrix during the first two weeks (K-M) but gradual macrophages and collagen were present at later
time points (N-0). P-T) Samples containing ketoprofen showed the similar pattern of cellular and
collagen infiltration as the control particles.
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Figure 4.4: Effects of hybrid drug-islet capsules on glycemic control of STZ-induced diabetic mice
transplanted with a marginal islet mass of 250 IE.
A-C) Phase contrast images of alginate microcapsules without any drug (A), with dexamethasone (E) and
curcumin (F). D) Daily non-fasting blood glucose level of STZ-induced diabetic C57B6/J mice transplanted
with control islet capsules (n=7), capsules containing dexamethasone (n=7) and curcumin (n=6) co-
encapsulated with islets isolated from Sprague-Dawley rats. Improved glycemic control and prolonged
graft function by islets co-encapsulated with curcumin. E) Fasting blood glucose level of the same groups
of mice during the IPGTT on day 60. Mice transplanted with islets co-encapsulated with curcumin were
able clear glucose most effectively compared to the other two microcapsule formulations. (*) and (#)
represent p<0.01 and p<0.05 respectively, indicating a statistically difference between the blood glucose
levels of mice with curcumin-loaded capsules and control capsules.
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Figure 4.5: Characterization of fibrotic pericapsular overgrowth on microcapsules retrieved 60 days
after transplantation into STZ-induced C57B6J diabetic mice.
A-C) Fluorescent images of retrieved control microcapsules (A) and microcapsules with dexamethasone
(B) or curcumin (C) after DNA staining with Hoestch 33342 dye. D-F) Phase contrast images of the same
control microcapsules (D) and microcapsules with dexamethasone (E) or curcumin (F). G-1) Histology
H&E sections of retrieved control microcapsules (G) and microcapsules with dexamethasone (H) or
curcumin (1). J) Quantification of fluorescent signals from the three types of retrieved microcapsules.
Each data point represent the average signal ± s.e.m (n=6 or 7)
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4.7. SUPPLEMENTARY INFORMATION
4.7.1. Supplementary results
4.7.1.1. Subcutaneous screening of different formulations of anti-inflammatory drugs
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Figure 4.6: In vivo subcutaneous screening of anti-inflammatory drugs encapsulated in PLGA
microparticles.
Data arranged in order of decreasing relative fluorescent or bioluminescent signals. A) Activity of
cathepsin enzymes was quantified using Prosense 680, a fluorescence-activated imaging probe. B)
Presence of reactive oxygen species was quantified using luminol which emits bioluminescence when
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oxidized by ROS. Relative fluorescent or bioluminescent signal was calculated as a ratio of the signal
from the drug-loaded microparticles to that from the control particles in the same mice. Each data point
represents the average signal ± s.e.m (n=6 replicate injections).
4.7.1.2. Temporal evolution of inflammation markers in the host response
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Figure 4.7: Temporal evolution of cathepsin enzymes and ROS in the host response to PLGA
microparticles with and without drugs.
A-C) Quantified time-lapse bioluminescent signals from PLGA microparticles with dexamethasone (A),
curcumin (B) and ketoprofen (C) in comparison with control PLGA microparticles in the first seven days
after subcutaneous injection. ROS activity was the highest in the first three days for the control particles.
During these three days, curcumin-loaded microparticles also showed the most significant suppression
of bioluminescent signals. (D-F) Quantified time-lapse fluorescent signals from PLGA microparticles with
dexamethasone (D), curcumin (E) and ketoprofen (F) in comparison with control PLGA microparticles
during the 28 days after subcutaneous injection. Cathepsin activity was the highest in the first 15 days
for the control particles. During these 15 days, dexamethasone-loaded microparticles also showed the
most significant suppression of fluorescent signals. Each data point represents the average signal ± s.e.m
(n=15 replicate injections).
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4.7.1.3. Analysis of excised PLGA microparticles to determine the presence of residual drugs
To determine whether the drugs were still present in the PLGA microparticles in the subcutaneous space
of SKH-1E mice, the microparticles were retrieved from mice sacrificed on day 28. Figure 4.8A-C showed
the excised polymer spots for the three different drugs; the presence of curcumin is evident by its
intrinsic yellow color in Figure 4.8B. Since ketoprofen and dexamethasone could not be visually detected
by their white color, the excised samples corresponding to these two drugs were liberated from
surrounding fibrotic tissue by collagenase digestion and analyzed by HPLC to determine the presence of
any remaining drug. HPLC analysis of these two samples (Figures 4.8D-E) confirmed that ketoprofen and
dexamethasone were present in the samples excised on day 28. Our ex vivo analysis proved that the
absence of inhibitory effects by ketoprofen (for the entire four week duration of the experiment) and
curcumin (after the first two weeks) was not due to the exhaustion of the encapsulated drugs. The data
confirmed that, despite their presence till day 28, ketoprofen and curcumin were not effective in
suppressing the infiltration of host immune cells in the subcutaneous space at these time points.
Dexamethasone Curcumin Ketoprofen
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9 a450
-sample before injection ~1mg/ml -sample before injection ~1mg/mI
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Figure 4.8: Ex-vivo analysis of PLGA microparticles excised from SKH1E mice at day 28.
A-C) Colored pictures of excised skin tissues containing PLGA microparticles with dexamethasone (A),
curcumin (B) and ketoprofen (C). The microparticles in (B) remained yellow indicating the presence of
curcumin. D-E) HPLC analysis of excised PLGA microparticles from (A) and (C) showed absorbance peaks
in (D) and (E) corresponding to dexamethasone and ketoprofen respectively. This data confirmed the
presence of these two drugs in the microparticles at day 28.
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4.7.1.4. Determination of marginal islet mass for transplantation in diabetic mice
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Figure 4.9: Blood glucose concentrations in STZ-induced diabetic C57B6/J mice depended on the
transplanted mass of encapsulated Sprague-Dawley rat islets.
In the range of 75-3001E, a higher islet mass resulted in lower average blood glucose level (n=3, error bar
represents s.e.m). With an islet mass of 3001E, the average blood glucose level remains close to
normoglycemic level (~200mg/dl) for about 2 weeks. An islet mass of 2501E was chosen as a marginal
mass for evaluation of hybrid drug/islet capsules.
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4.7.1.5. Establishing DNA fluorescent staining as a quantitative method for fibrosis assessment
To validate that DNA fluorescent staining with Hoestch 33342 dye can be used as a method to quantify
fibrosis formation on retrieved capsules, we stained 20 samples of capsules retrieved on day 60 after
intraperitoneal transplantation into STZ-induced diabetic mice. Each sample was visually observed under
a light microscope by five different blinded investigators who gave semi-quantitative scores for the
percentage of fibrotic capsules. The quantified fluorescent signal from each sample was plotted against
the average score from the visual observation (Figure 4.5C) confirming a good linear correlation
between the two methods (R2 =0.883).
In addition, we also stained control samples of the same volumes of empty alginate capsules and
encapsulated islets. Both of these samples were freshly prepared and have not been exposed to in vivo
environment. The samples of freshly encapsulated islets contained islets at a pre-encapsulation density
of 10001E/mI of alginate. Assuming each islet equivalent was a sphere of 150um diameter, the volume
occupied by the islet tissue was approximately 0.18% the total volume of alginate. At this low islet
density, the amount of islet DNA was so minimal that the fluorescent signal from the freshly
encapsulated islets was the same as that from the empty alginate capsules (Figure 3.5D). The data in
Figure 4.5D also confirmed that these two control samples did not emit significant fluorescent signals
compared to the transplanted capsules retrieved from diabetic mice. Therefore, we could confirm that
the measured fluorescent signals from the retrieved capsules primarily came from the DNA of fibrotic
cell layers and not from DNA of the encapsulated islets.
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Figure 4.10: DNA fluorescent staining correlated with fibrosis scoring by observation.
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A) Fluorescent image of retrieved capsules showing blue fluorescent signal for fibrotic capsule and no
fluorescence from clean capsules. B) Phase contrast image of the same capsules showing fibrotic
capsules covered with darker cell layers and transparent clean capsules. C) Linear correlation with an R-
square value of 0.883 between quantified DNA fluorescent signals and average percentage of fibrotic
capsules as visually scored by 5 blinded investigators. D) No significant fluorescent signal was detected
for the same volume of freshly prepared empty alginate capsules or capsules containing islets at a
density of 1000 IE/ml.
4.7.1.6. Residual drugs from hybrid islet-drug capsules explanted after two months
Control Dex Curcumin
SiiP SOs SO[I
Figure 4.11: Comparison of alginate capsules containing islets before transplantation and after
retrieval from C57B6/J diabetic mice on day 60.
A-C) Freshly prepared capsules containing rat islets with or without drug. Control capsules without drug
(A) were transparent while capsules with dexamethasone (B) appeared cloudy white and capsules with
curcumin (C) appeared yellow due to the intrinsic color of the drugs. D-F) Capsules explanted on day 60
after transplantation into STZ-induced diabetic C57B6/J mice. Control capsules (D) and capsules with
dexamethasone (E) were covered with fibrotic cell layers while capsules with curcumin (F) remained
mostly free of overgrowth. G) Colored photographs of eppendorf tubes containing the same freshly-
prepared capsules as shown in A-C. From left to right are control capsules, capsules with
dexamethasone and with curcumin respectively. H) Colored photographs of eppendorf tubes containing
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the same explanted capsules as shown in D-F. From left to right are explanted control capsules, capsules
with dexamethasone and with curcumin respectively. The yellowish color of the retrieved curcumin-
containing capsules indicated the presence of residual curcumin.
4.7.2. Supplementary materials and methods
4.7.2.1. Detection of residual drug in ex-vivo tissue by HPLC analysis
PLGA microparticles with encapsulated drugs and surrounding tissue were retrieved 28 days after
subcutaneous injection. The microparticles and their surrounding fibrotic cellular layers were gently
detached from the skin tissue and placed in an Eppendorf tube containing 1.5ml of 0.2% (w/v) solution
of collagenase enzyme type IV (Invitrogen) in Ca2+/Mg 2+ free HBSS buffer . The tube was placed on a
rotational shaker (LabQuake) and incubated at 370C for 45min with vortexing at every 15 minute interval
till all the collagen surrounding the microparticles were digested and the microparticles were released
from the fibrotic cell layers. The particles were then washed in deionized water three times to remove
the collagenase, flash-frozen with liquid nitrogen and lyophilized till dryness. These lyophilized particles
were dissolved in acetonitrile at a concentration of 8-10mg/ml and analyzed with a HPLC (Agilent
Technology) following protocols previously reported. The analysis was performed using an Atlantis dC-
18 5um 4.6x250mm reverse phase column (Waters) and a mobile phase of 35:65 (v/v) phosphate buffer
to acetonitrile at a constant flow rate of 1ml/min. Sample detection by UV absorbance was recorded at
246 nm and 256nm for dexamethasone and ketoprofen respectively. Drug-loaded microparticles, which
have not been injected into SKH1E mice, were also analyzed using the same HPLC methods but at a
concentration of 1mg/ml in acetonitrile.
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CHAPTER 5 - MICROFABRICATION OF CELIAADEN, ASYMMETRIC
HYDROGEL MICROCAPSUIEJUS
The content of this chapter has been published in whole or in part in the following peer-reviewed
journal article:
Dang TT Xu Q, Bratlie KM, O'Sullivan ES, Chen XY, Langer R, Anderson DG. "Microfabrication of
Homogeneous, Asymmetric Cell-laden Hydrogel Capsules." Biomaterials 2009; 30(36): 6896-6902
5.1. ABSTRACT
Cell encapsulation has been broadly investigated as a technology to provide immunoprotection for
transplanted endocrine cells. Here we develop new fabrication methods that allow for rapid,
homogenous microencapsulation of insulin-secreting cells with varying microscale geometries and
asymmetrically modified surfaces. Micromolding systems were developed using polypropylene mesh,
and the material/surface properties associated with efficient encapsulation were identified. Cells
encapsulated using these methods maintain desirable viability and preserve their ability to proliferate
and secrete insulin in a glucose-responsive manner. This new cell encapsulation approach enables a
practical route to an inexpensive and convenient process for the generation of cell-laden microcapsules
without requiring any specialized equipment or microfabrication process.
5.2. INTRODUCTION
Cell encapsulation is a strategy to allow for the transplantation of non-autologous cells without the
use of immunosuppressive drugs, which have potentially severe side-effects [20, 186-188].
Transplanted living cells are protected from the host immune system because they are encapsulated in a
semi-permeable hydrogel membrane which allows the diffusion of nutrients and cellular metabolic
products while excluding antibodies and immune cells [189]. This technique has potential applications as
therapies for many diseases such as diabetes, hormone deficiencies or hepatic failure [188].
Encapsulated islets have been explored as a method to allow transplantation of allogenic or
xenogeneic insulin-secreting cells into diabetic hosts [190-195]. Electrostatic droplet generation is the
most widely used method in the production of microcapsules containing islets or other insulin-secreting
cells[196]. Typically, a laminar liquid jet is broken into droplets by a harmonically vibrating nozzle
combined with an electrostatic dispersion mechanism which prevents droplet aggregation [197].
Currently, droplet generator encapsulation systems are commercially available from several
manufacturers such as Inotech Biosystem (Rockville, MD) and Nisco Engineering AG (ZOrich,
79
Switzerland). The electrostatic droplet generator system is appropriate for the continuous production of
hydrogel microcapsules (200-600 pm in diameter) from a polymer/cell mixture of an unchanged
composition [197]. However, this apparatus, which requires sterilization of the bioreactor chamber after
each use, is not convenient for studies which involve screening a large number of different material
formulations [198]. Furthermore, this approach does not allow for generation of non-spherical capsules.
Therefore, it is desirable to develop new and convenient methods for fast generation of geometrically
controlled, cell-laden microcapsules.
Soft-lithography with PDMS molds has been used to fabricate alginate hydrogel microcapsules in
2D arrays as well as discrete single modules [199-202]. Many living cells, including bacteria and
mammalian cells, have been encapsulated in hydrogels with this approach [199-202]. However, a
potential challenge for this technique is the difficulty of releasing the microcapsules from the PDMS
mold without damaging the cells. Even though methods such as mechanical stretching of the mold,
swelling the hydrogel capsules in organic solvent[199] or microtransfer molding [201, 203] have been
applied to facilitate capsule release, these processes decrease cell viability and capsule yield [201, 202].
Whitesides et al. recently demonstrated the production of cell-laden microcapsules using a PDMS
membrane with fully penetrating pores to improve the ease of capsule retrieval [204]. However, this
method is still limited by the necessity of a microfabrication process to generate the PDMS membranes
and the difficulty of obtaining membranes of large area.
Here, we describe an inexpensive and convenient approach utilizing a commercially available
polypropylene mesh for the fabrication of cell-laden hydrogel microcapsules without using any
specialized equipment or microfabrication processes. The in vitro viability, proliferation and insulin
secreting function of the encapsulated cells were characterized. We also demonstrated the fabrication
of capsules with different geometries and selective modification of the microcapsule surface using this
mesh-based fabrication approach.
5.3. MATERIALS AND METHODS
5.3.1. Fabrication of alginate hydrogel capsules
Thermo-molded plastic meshes were purchased from McMaster-Carr and Industrial Netting. The
plastic meshes were cut into pieces of 4x3 cm 2 and placed in a Chex-all* 11 instant sealing pouch. These
meshes were autoclaved at 121 0C and kept sterile until use. Sodium alginate (FMC BioPolymer, LF 10/60
LS), with or without materials to be encapsulated, was dissolved in 0.9% NaCl solution at a concentration
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of 1.5wt%. When encapsulation of microspheres or cells was desired, 1wt% solid solution of 1tm red
fluorescent microspheres (Invitrogen, Eugene, OR) were diluted 500-fold with this 1.5wt% alginate
solution while INS-I cells were suspended in alginate at a density of 1.5x106cells/mL. The resulting
mixture was vortexed to obtain a homogeneous mixture which was then centrifuged at 200xg for three
minutes. The air bubbles at the top of the mixture were removed by aspiration before this suspension
was poured into a sterile Petri dish. A piece of sterile mesh was lightly dipped onto the cell/alginate
mixture with the less reflective surface of the mesh in contact with the suspension. Excess alginate was
removed by gently wiping the mesh against the edge of a sterile Petri dish. The mesh was immediately
immersed in a solution of 100 mM CaC 2 and subsequently transferred to HEPES buffer (132mM NaCl,
4.7mM KCI, 25mM HEPES, 1.2mM MgCI2) for mild washing. The hydrogel capsules were finally released
by holding the mesh with a pair of tweezers and gently agitating it in a collecting solution.
5.3.2. Asymmetric surface modification of hydrogel capsules
Before the capsules were released from the mesh template into the collecting solution, one side of
the mesh containing cross-linked hydrogels were gently placed on the liquid surface of a 4mg/mL
solution of 40-7OkDa FITC-labeled poly-L-lysine (Sigma Aldrich, St Louis, MO) for 3 minutes. The mesh
was then gently washed in HEPES buffer before the capsules were released into a collection medium.
5.3.3. Cell culture
The rat insulinoma cell line (INS-1) was a gift from the Joslin Diabetes Center (Boston, MA). INS-i
cells at passages of 7-20 were cultured according to a protocol previously described [205]. The cells
were cultured in complete medium composed of RPM1 1640 supplemented with 10 mM HEPES, 10%
heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin,
1 mM sodium pyruvate, and 50 p.M 2-mercaptoethanol. Cultures were incubated at 37 *C in a humidified
95% air-5% CO2 atmosphere and manipulated under sterile tissue culture hoods. Confluent dish of INS-i
cells was passaged every week at a subculture ratio of 1:3 and fed every 2-3 days. For trypsinization, the
adherent cells were exposed to 0.025% trypsin-EDTA solution to yield a cell suspension which was
centrifuged at 150xg at 4 *C for 3 min. For preparation of frozen cell stock, freshly trypsinized cells were
suspended in complete medium containing 10% of dimethyl sulfoxide and kept at -80 0C overnight in a
Nalgene* Cryo Freezing container before being transferred to liquid nitrogen for long-term storage.
5.3.4. Viability analysis of encapsulated cells
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The viability of INS-1 cells in alginate microcapsules was characterized using the Live/Dead*
Viability/Cytotoxicity Assay Kit (Molecular Probe, Carlsbad, CA). Microcapsules were incubated in HEPES
buffer containing fluorescent dyes at the concentrations of 2 pM Calcein-AM and 12 gM ethidium
homodimer-1 for 45 minutes. The capsules were washed with HEPES buffer and visualized under a
Nikon TE 300 inverted microscope under either phase contrast or fluorescent microscopy settings.
Green fluorescence was viewed under a FITC filter and red fluorescence under a TRITC filter. Images
were photographed using a CCD camera and Metamorph imaging software (Molecular Devices,
Sunnyvale, CA). Confocal images were taken using a Zeiss LSM 510 confocal microscope with an argon
excitation source. For live cell imaging, excitation wavelength of 488 nm and a filter set of 505-537 nm
were used. Dead cells were imaged using an excitation wavelength of 543 nm and an emission filter set
of 559-623 nm.
5.3.5. Static glucose-stimulated insulin secretion
Five 500 Il aliquots of microcapsules containing INS-1 cells were cultured over a period of 10 days.
At the desired time points, the capsules were subjected to a static glucose stimulation study following a
procedure slightly modified from a protocol elsewhere [206]. Briefly, the capsule samples were pre-
incubated for one hour in Krebs Ringer buffer Hepes (KRBH) (137 mM NaCl, 4.8 mM KCI, 1.2 mM
KH2PO4, 1.2 mM MgSO47H20, 2.5 mM CaCl2-2H20, 5 mM NaHCO3, 16 mM HEPES, 0.1% (w/v) BSA, pH
7.4) containing 2.8 mM glucose. The in vitro insulin secretion was then assessed by consecutive
incubations of the capsules in 4 mL of KRBH containing 2.8 mM glucose or 16.8 mM glucose for one
hour. The samples were kept at 37 *C in humidified air and 5% C02 for the duration of the pre-
incubation and stimulation. The capsules were washed with HEPES buffer in between two incubations to
remove residual insulin. At the end of each incubation, 1000 pl of the KRBH was removed and frozen at -
20 0C for storage before insulin assay. Insulin concentrations were determined using Ultrasensive EIA
assay kits (ALPCO Diagnostics, Salem, NH).
5.4. RESULTS AND DISCUSSION
5.4.1. Properties of template meshes for successful capsule fabrication
We fabricated the alginate hydrogel microcapsules using a process illustrated in Figure 5.1. Briefly,
the sterile polymer mesh with an array of uniform pores is brought in gentle contact with the alginate
solution (1.5% w/v aqueous solution) with or without materials to be encapsulated. After capillary force
completely fills the pores with the alginate solution, the mesh is held vertically so that most of the
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excess alginate is removed by gravity. The mesh surface was subsequently wiped against the flat edge of
a sterile petri dish to further remove any excess alginate. This polymer mesh containing uniform pores
filled with alginate was immediately dipped into an aqueous solution of calcium chloride which cross-
links the alginate polymer chains in to a hydrogel. After mild washing in HEPES buffer, the hydrogel
microcapsules are released by holding the mesh with a pair of tweezers and gently agitating it in a
collection solution of culture medium. Figure 5.2A shows large sheets of thermo-molded polypropylene
mesh and Figure 5.2B is a mesh template with an array of uniform pores typically used in this fabrication
process. Figures 5.2C and 5.2D shows the different pore shapes of the polypropylene meshes from
McMaster-Carr and Industrial Netting respectively.
After testing several types of commercial polymer meshes from different suppliers, we determined
that the surface properties of the polymer mesh are critical for successful fabrication of individual
alginate capsules. Table 5.1 shows the feasibility of capsule formation and retrieval for a variety of
thermoplastic meshes manufactured from nylon, polypropylene and Teflon. Filling of mesh pores by
alginate solution was classified as easy (+) for instant pore wetting and liquid retention or as difficult (-)
if the alginate failed to remain in the pores. Capsule retrieval was considered easy (+) if more than 80%
of the freestanding microcapsules are released from the mesh pores instantly during the agitation step.
If the capsules formed are connected by a thin film of residual alginate, the retrieval process is
considered difficult (-). We observed that meshes made from Teflon are too hydrophobic and the
alginate solution is unable to fill the pores. This is similar to observations of trapped air bubbles in PDMS
molds[199] and membranes [204] due to the hydrophobic nature of PDMS before surface treatment by
oxygen plasma. On the other hand, nylon meshes are too hydrophilic and the alginate solution forms
interconnected capsules easily, even after the excess alginate is removed by wiping against the edge of
the petri dish. Only polypropylene mesh appears to possess appropriate surface property which enables
fabrication of individual free-standing capsules. Furthermore, polypropylene has a high heat-resistant
ability which makes it desirable for cell encapsulation applications. Its softening and melting
temperatures of 152 0C and 161 0C respectively ensure that the mesh property is unaffected during
autoclave sterilization at 121 0C.
5.4.2. Fabrication of hydrogel capsules with different shapes and asymmetrically
modified surfaces
Various microcapsule shapes can potentially be useful as building blocks for engineering of 3D
tissue constructs or investigating the effect of hydrogel geometries on the viability, proliferation and
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functions of encapsulated cells [207, 208]. Figure 5.3A and 5.3B shows microscopy images of alginate
hydrogel capsules fabricated from different mesh templates to produce capsules with rectangular
cuboidal and cylindrical shapes. The non-spherical geometries achieved with this mesh template
technique complement the spherical capsules produced by conventional droplet generator systems. We
are also able to modify a selected surface of the microcapsules by dipping one side of the mesh
containing cross-linked hydrogels onto a desired coating material. Figure 5.3C and 5.3D show a bead-
encapsulating capsule with FITC-labeled poly-L-lysine modifying a selected surface. Figure 5.3C is the
confocal image with only red fluorescence displayed, showing red 1 IIm beads encapsulated in a
rectangular cuboidal capsule. In Figure 5.3D, the same capsule is visualized with both red and green
fluorescence channels, indicating that a green layer of positively-charged FITC-Poly-L-Lysine was
selectively coated on one side of the negatively charged alginate capsule. Such asymmetrically modified
capsules with two surfaces of opposite charges might have applications in the directed assembly of cell-
laden hydrogel capsules for fabrication of 3D tissue constructs [207].
5.4.3. Fabrication of hydrogel capsules containing insulin-secreting cells
To illustrate the applicability of this technique in the encapsulation of insulin-secreting cells, we
chose a cell line (INS-1) derived from x-ray-induced insulinoma in rats[205] to fabricate cell-laden
hydrogel microcapsules. Alginate microcapsules containing these cells were fabricated following the
procedure shown in Figure 5.1 using a suspension of INS-1 cells in 1.5% alginate. Since the presence of
cells has an important effect on the rheological properties of alginate, a series of experiments were
performed to identify optimal maximum cell-packing density (data not shown). Figures 5.4A and 5.4B
shows cell-laden microcapsules fabricated using polypropylene meshes from McMaster (Item #9265T41)
and Industrial Netting (Item # XN6080) respectively. The initial cell densities in these microcapsules are
in the optimal range of 1.5 - 2.0x10 6 cells/cm3 . This range of maximum initial cell density is comparable
to that achieved with the conventional droplet generation method [197].
5.4.4. Assessment of viability, proliferation and function of encapsulated cells
5.4.3.1. Fabrication of hydrogel capsules containing insulin-secreting cells
We studied the viability and proliferation behavior of the encapsulated cells cultured in vitro for a
period of ten days. Figures 5.4C and 5.4E show the phase contrast and fluorescent images of the three-
day microcapsules fabricated from mesh XN6080 with live/dead staining. This viability assay
differentiates live and dead cells on the basis of intracellular esterase activity and plasma membrane
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integrity. In this assay, live cells fluoresce green due to the presence of intracellular esterase which
converts the nonfluorescent cell-permeable calcein-AM to an intensely green fluorescent product. On
the other hand, ethidium homodimer-1 permeates compromised cell membranes and result in the red
appearance of dead cells when this dye undergoes enhanced fluorescence upon binding to cellular
nucleic acids. After three days in culture, more than 80-90% of the cells were still alive. These viable
single cells appeared as individual green dots in Figure 5.4E while some dead cells stained red were also
observed. This small fraction of dead cells possibly arose from the original cell stocks or from minimal
cell injury during the encapsulation process. After ten days in culture, the encapsulated cells have also
proliferated and formed larger clusters as observed in Figure 5.4D and 5.4F. The ten-day hydrogel
capsules contained mostly viable cells as shown in Figure 5.4F. Confocal microscopy was also used to
examine the 3D distribution of cells throughout the entire microcapsule. Figure 5.5A shows a single
capsule at high magnification. Figure 5.5B is the combined projection of multiple images taken at
different depths of the same capsule (each optical slice is of 2.5 Ipm for a total thickness of 200 ptm).
Figure 5.5C shows a projected image of the capsule along its diagonal confirming that most cell clusters
are alive. These cell clusters are about 20-50 prm in diameter. They are also uniformly viable and
homogeneously distributed in all spatial dimensions of the capsules. These results indicate nutrient
transport throughout this capsule geometry is sufficient to maintain cell viability and proliferation.
5.4.3.2. Static glucose-stimulated insulin secretion
We also performed a static glucose challenge to assess the ability of the encapsulated INS-1 cells to
maintain their desired glucose-responsive functions. Figure 5.6 shows the insulin secretion from the cell-
laden capsules cultured over a period of ten days in response to two different glucose concentrations.
Glucose levels of 2.8 mM and 16.5 mM were used to simulate the physiological basal and hyperglycemic
conditions of diabetic patients respectively. At all time points investigated (3 days, 6 days and 10 days)
the encapsulated cells were able to maintain the desired glucose-responsive behavior. These cells
secreted a higher insulin concentration (1.5 to 3-fold) when subjected to the higher glucose level. The
absolute amount of insulin secreted also increases over time confirming that the cells are proliferating in
the capsules.
5.5. CONCLUSION
Here we have developed an approach for the fabrication of alginate microcapsules containing
functional insulin-secreting cells. This technique can be utilized to fabricate non-spherical capsules of
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different geometries and unlike conventional droplet methods, allows for asymmetric modification of
the surfaces of the microcapsules. The surfaces of such capsules can be asymmetrically tailored with
functional coatings of different charges or polarities to introduce directionality to the capsules. This
strategy potentially allows for the directed assembly of cell-laden hydrogel capsules by controlling their
alignments and orientation for the generation of biomimetic tissue constructs with desired microscale
architecture and complexity. In addition, the polymer mesh is mechanically and thermally robust. Thus
it can be easily handled and sterilized by autoclaving. The entire encapsulation process using the
polypropylene mesh can be conveniently carried out inside a sterile tissue culture hood. This mesh-
based method offers a complementary approach to the existing droplet generator system for the
fabrication of cell-laden hydrogel capsules. We believe that utilizing an inexpensive and commercially
available mesh offers straightforward access to tissue engineers and biologists as this avoids any
specialized equipment, making this approach more convenient for widespread use in biological
laboratories.
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Table 5.1: Relationship between the feasibility of microcapsule formation and the properties of a
variety of thermoplastic meshes.
Pore filling and capsule release are classified as easy (+) or difficult (-). Assessment of capsule release is
not applicable (n/a) if pore filling is unsuccessful. All other meshes were purchased from
IndustrialNetting, except mesh 9265T41(*) from McMaster-Carr.
Sample ID Mesh Pore shape Estimated pore Estimated Pore Capsule
Material dimension mesh filling with release
(um) thickness (um) alginate
NN-1400 Nylon-6 square 890x890 380 (+) (-)
NN-1500 Nylon-6 square 710x710 380 (+) (-)
NN-1800 Nylon-6 square 380x380 510 (+) (-)
NN-1700 Nylon-6 square 250x250 510 (+) (-)
9265T41 (*) Polypropylene rectangular 530x690 300 (+) (+)
XN-6080 Polypropylene rectangular 530x690 360 (+) (+)
XN-6070 Polypropylene rectangular 630x760 360 (+) (+)
XN-7110 Polypropylene circular 650 (diameter) 360 (+) (+)
ET-8300 PTFE diamond 1140x630 460 (-) (n/a)
ET-8120 PTFE diamond 630x130 200 (-) (n/a)
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Poly(propylene) mesh
alginate solution with cells 100mM CaCl, solution Culture medium
Figure 5.1: Schematic illustration of the procedure to fabricate alginate microcapsules
The mesh template is dipped into an alginate solution with or without cells and transferred to a 100mM
CaCl 2 solution for cross-linking. Hydrogel microcapsules are released by gently agitating the mesh in cell
culture medium.
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Figure 5.2: Images of polypropylene meshes used for microcapsule fabrication.
(A) Photograph of large sheets of thermo-molded polypropylene mesh utilized in microcapsule
fabrication. (B) Light microscopy images of mesh templates with an array of uniform pores.
Polypropylene meshes with rectangular (C) and circular pores (D).
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Figure 5.3: Microcapsules with different geometries and asymmetric modification.
Light microscopy image of rectangular cuboidal (A) and cylindrical (B) hydrogel capsules. Confocal
microscopy images of a rectangular cuboidal capsule encapsulating red fluorescent microbeads with
only red fluorescence displayed (C) and the same capsule with both red and green fluorescences
displayed (D). A green layer of FITC-Poly-L-Lysine was coated on one side of the capsule. All scale bars
represent 200ptm
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Figure 5.4: Light and fluorescent microscopy images of alginate microcapsules containing INS-1 cells.
Microcapsules fabricated using (A) mesh 9265T41 and (B) mesh XN-6080 at cell densities of 1.5x106
cells/mL and 2.0x106 cells/mL, respectively. Three-day capsules (C) contain single cells which proliferate
into larger clusters after ten days (D). Staining of the same capsules with viability markers shows that
three-day single cells (E) and ten-day cell clusters (F) maintain good viability. All scale bars represent
300pm.
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Figure 5.5: Viability and homogeneous distribution of cell clusters in a single microcapsule.
(A) Differential Interference Contrast image of a single microcapsule containing INS-1 cell clusters after
ten days in culture. Confocal microscopy of the top view (B) and side view (C) along the diagonal of the
same capsule shows homogeneous cell distribution and viability. Dashed line indicates the edge of the
microcapsule. All scale bars represent 100plm.
0)E
C:
0
.Ac)
0
C:
-5
Cl)
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
16.5mM glucose
0 2.8mM glucose I
T
T
3 6
Post-encapsulation
10
time (days)
Figure 5.6: Insulin secretion of encapsulated INS-1 cells over a period of ten days.
Values are the mean (± S.D) from five independent experiments. Cells maintain glucose-responsive
function; and insulin secretion also increased over time confirming cell proliferation.
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CHAPTER 6 - CONCLUSION AND RECOMMENDATION FOR FUTIJRE WORK
6.1. CONCLUSION
In this thesis research, new non-invasive imaging techniques have been developed for parallel in
vivo biocompatibility analysis of multiple materials and drug formulations using time-lapse fluorescent
and bioluminescent imaging. Systematic subcutaneous in vivo screening of several classses of small
molecule anti-inflammatory drugs was performed using the new imaging techniques to understand their
effects on the biomaterial-induced generation of reactive oxygen species and inflammatory proteases.
Dexamethasone and curcumin were selected from the screening study for incorporation into hybrid
hydrogel microcapsules co-encapsulating donor pancreatic islets for evaluation in a mouse model of
chemically induced diabetes. The results demonstrated that the hybrid capsules containing curcumin led
to reduced fibrotic response to encapsulated islets and improved their efficacy in glycemic control.
6.2. RECOMMENDATION FOR FUTURE WORK
Firstly, improved release kinetics of the anti-inflammatory agents can potentially be achieved by
covalently attachment of the drug, such as dexamethasone, to the hydrogel polymer forming the
capsule via a degradable linking moiety such as an ester group or a hydrazide group. Hydrolysis of
linking ester groups in vivo can release dexamethasone at a slower rate over an extended period of
time. Alternatively, anti-inflammatory drugs can also be encapsulated in drug-loaded biodegradable
polymeric particles for controlled release. However, the choice of the polymer for the fabrication of
these particles must be selective to avoid degradation products that might stimulate an unfavorable
immune response or become toxic to the encapsulated cells.
Secondly, a combination of several anti-inflammatory agents might have the potential to act
synergistically to suppress immune responses against non-self materials. However, the effects of
potential overdose, systemic toxicity or drug interference must be carefully considered.
Thirdly, the drug or drug-loaded polymer particles and the therapeutic cells may be
compartmentalized within the hydrogel capsules. Compartmentalizing the drug to the surface of the
hydrogel capsules facilitates outward drug diffusion, maximizes drug interaction with immune cells, and
minimizes its interference with the mammalian cells inside. A next generation of hybrid drug-islet
capsules can be designed to have a core-shell structure in which the cells are encapsulated in the inner
core and the anti-inflammatory drugs or drug-loaded polymeric particles are encapsulated within an
external shell. The core and shell can be separated by a polycation membrane. Alternatively, core-shell
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capsules might be fabricated without a membrane layer using a microfluidic or needle system to form
microcapsules with two integrated layers. For example, two con-current liquid streams may be used to
form two-layer droplets with the external stream containing the desired drug composition.
Lastly, a planar macro-device encapsulating therapeutics cells can be designed to have one
device surface coated with a biocompatible adhesive containing the anti-inflammatory drug or drug-
loaded particles. The device can be glued against peritoneal or subcutaneous tissue surface. The anti-
inflammatory drug released from the device can help to modulate the host response to the device and
improve the efficacy of the encapsulated cells.
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APPENDIX A - ABBREVIATIONS
ANOVA Analysis of Variance
DNA Deoxy-ribonucleic Acid
FDA Food and Drug Administration
FITC Fluorescein isothiocyanate
H&E Hematoxylin and Eosin
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HPLC High-Performance Liquid Chromatography
ID Inner Diameter
IE Islet Equivalent
IPGTT Intra-Periotoneal Glucose Tolerance Test
ISO International Organization for Standardization
LOQ Limit of Quantification
LSD Least Significant Difference
NSAID Non-steroidal Anti-inflammatory Drug
OD Outer diameter
PBS Phosphate buffered saline
PLGA Poly(lactic-co-glycolic acid)
PMN Polymorphonuclear
ROI Region of Interest
ROS Reactive Oxygen Species
SEM Scanning Electron Micrograph
STZ Streptozotocin
Wt% weight percentage
v/v volume to volume
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Homogeneous, Asymmetric Cell-laden Hydrogel Capsules." Biomaterials 2009; 30(36): 6896-6902
. Xu Q, Hashimoto M, Dang TT Hoare T, Kohane DS, Whitesides GM, Langer R, Anderson DG.
"Preparation of Monodisperse Biodegradable Polymer Microcaparticles Using a Microfluidic Flow-
Focusing Device for Controlled Drug Delivery". Small 2009; 5(13): 1575-1581
PATENTS
. Anderson D.G, Langer R, and Dang TT. "Hybrid Microcapsules containing islets and anti-inflammatory
drugs for diabetes therapy". U.S.S.N. 61/444206, filed on Feb. 2011.
. Anderson D.G, Langer R, and Dang TT. "Hydrogel-encapsulated cells and anti-inflammatory drugs".
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CONFERENCE PRESENTATIONS AND POSTERS (presenters underlined)
. Dang TT, Bratlie KM, Bogatyrev SR, Chen XY, Langer R, Anderson DG. "Spatiotemporal effects of a
controlled release anti-inflammatory drug on the cellular dynamics of host response". Biomedical
Engineering Society Annual Meeting, Hartford, CT, Oct 1 2th- 14 t' 2011 (oral presentation)
. Dang TT, Bratlie KM, Bogatyrev SR, Chen XY, Langer R, Anderson DG. "Spatiotemporal effects of a
controlled release anti-inflammatory drug on the cellular dynamics of host response". Gordon
Research Conference on Biomaterials and Tissue Engineering, Holderness, NH, July 3 1st- Aug 5th 2011
(poster presentation)
. DangTT, Bratlie KM, Bogatyrev SR, Chen XY, Langer R and Anderson DG "Investigating the Effect of
Anti-Inflammatory Drugs On Material Biocompatibility by In Vivo Fluorescent Imaging". American
Institute of Chemical Engineering Annual Meeting, Salt Lake, Utah, Nov 7th _12th 2010 (oral
presentation)
. Bratlie KM, Dang TT, Vegas AJ, Vietti TM, Langer R and Anderson DG. " Determining Biocompatibility of a
Chemically Modified Alginate Library through In Vivo Imaging and Histology". American Institute of
Chemical Engineering Annual Meeting, Salt Lake, Utah, Nov 7th 12 th 2010.(oral presentation)
. Dang TT, Bratlie KM, Bogatyrev SR, Chen XY, Langer R and Anderson DG "Investigating the Effect of Anti-
Inflammatory Drugs On Material Biocompatibility by In Vivo Fluorescent Imaging". American Chemical
Society National Meeting, Boston, Aug 2 0 th -26 th 2010 (oral presentation)
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. DangTT, Xu 4 Bratlie KM, O'Sullivan ES, Chen XY, Langer R, Anderson DG. "Microfabrication of
Asymmetric, Homogenous Cell-Laden Hydrogel Microcapsule". The 1 0 th US-Japan Drug Delivery
Symposium, Hawaii, Dec 16th - 20 th 2009 (poster presentation)
. Dang TT, Xu 4, Bratlie KM, O'Sullivan ES, Chen XY, Langer R, Anderson DG. "Microfabrication of
Asymmetric, Homogenous Cell-Laden Hydrogel Microcapsule" Material Research Society Meeting,
Boston, Nov 30th -Dec 2 nd 2009 (oral presentation)
. Xu Q, Hashimoto M, Dang TT Hoare T, Kohane DS, Whitesides GM, Langer R, Anderson DG.
"Preparation of Monodisperse Biodegradable Polymer Microcaparticles Using a Microfluidic Flow-
Focusing Device for Controlled Drug Delivery". Material Research Society Meeting, Boston, Nov 3 0 th _
Dec 2nd 2009 (poster presentation)
. Dang TT, Gao S, Erathodiyil N, Ying JY. "Hydrogels and nanoparticles for glucose-responsive insulin
delivery". A*STAR research symposium, Singapore, July 2007 (oral presentation)
. Dang TT, Gao S, Erathodiyil N, Ying JY. "Synthesis and characterization of glucose-responsive insulin-
delivery hydrogel and nanoparticles for diabetes treatment" International Conference on the
Development of Biomedical Engineering, Hanoi, Vietnam, July 2007 (oral presentation)
. Dang TT, Chubiz Lon and Rao CV. "Evolution of chemotaxis proteins in proteobacteria" International
Conference on the Development of Biomedical Engineering, Hanoi, Vietnam, July 2007 (poster
presentation)
TEACHING & MENTORING EXPERIENCE
9/2010-present
1/2008-present
5/2009-8/2009
9/2011-5/2012
9/2009-12/2009
Research mentor, recruited, trained and supervised two full-time research
technicians (B.Sc in Biology and Chemical Engineering) to support a project,
funded by the Juvenile Diabetes Research Foundation, to improve immuno-
isolation of pancreatic islets for diabetes therapy.
Research mentor, supervised four Undergraduate Research Opportunity Scholars
(UROPs) from different departments at MIT : Chemical Engineering, Material
Science and Engineering, Biomedical Engineering and Biology
Research mentor, supervised Xiao Chen's summer research UROP proposal which
won the MIT-UROP Howard Hughes Medical Institute summer fellowship to
conduct research in the laboratory of Professor Robert Langer
Teaching certificate program participant, attended a series of monthly
workshops at MIT on teaching techniques to enhance student-teacher
communication.
Graduate Teaching Assistant in the Department of Chemical Engineering, MIT,
assisted Prof. Gregory Rutledge and Dr Barry Johnston in an undergraduate
course "Introduction to Chemical Engineering".
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COMMUNITY and OUTREACH ACTIVITIES
3/2012-4/2012
9/2011
10/2011
2008-2011
7/2006-7/2007
Clinical Preceptorship Participant, shadowed Dr John D'Elia at the Joslin Diabetes
Center, Harvard Medical School to observe clinical care of patients with diabetes
and kidney failure.
Abstract reviewer, evaluated student abstracts for the Annual Biomedical Research
Conference for Minority Student (ABRCMS) in St Louis, Missouri, 2011
Graduate Career Panelist, advised undergrad students in the MIT Society of Asian
Engineers and Scientists on graduate career paths.
Volunteer, contributed to set-up of experiment demonstration and gave lab tours
to high school students visiting the laboratory of Professor Langer at MIT.
Chemistry teacher/volunteer at a Singapore high school, Victoria Junior College
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